0001 Rec'd PCT/PTO 20 DEC 2001

FORM PTO-1390 (Modified) (REV 11-2000) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER **27656/38053**

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 10/019098

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/IB99/01166	**22 June 1999**	**NONE**

TITLE OF INVENTION
IN VIVO INSECT MODEL SYSTEM FOR TYPE-2 DIABETES

APPLICANT(S) FOR DO/EO/US
HAFEN, Ernst

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include itens (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
   - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
   - b. ☒ has been communicated by the International Bureau.
   - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   - a. ☐ is attached hereto.
   - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   - b. ☐ have been communicated by the International Bureau.
   - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Corrected International Preliminary Examination Report; Sequence Listing in paper form; Sequence Statement pursuant to 37 C.F.R. 1.821-1.825; and Return receipt post card.

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
10/019098	PCT/IB99/01166	27656/38053

24. The following fees are submitted:.		CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :			
☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	**$1040.00**		
☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	**$890.00**		
☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	**$740.00**		
☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	**$710.00**		
☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	**$100.00**		
ENTER APPROPRIATE BASIC FEE AMOUNT =		**$890.00**	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).		**$0.00**	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	34 - 20 =	14	x $18.00	**$252.00**	
Independent claims	3 - 3 =	0	x $84.00	**$0.00**	
Multiple Dependent Claims **(check if applicable)**.			☐	**$0.00**	
TOTAL OF ABOVE CALCULATIONS =				**$1,142.00**	
☐ Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				**$0.00**	
SUBTOTAL =				**$1,142.00**	
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +				**$0.00**	
TOTAL NATIONAL FEE =				**$1,142.00**	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) **(check if applicable).** ☐				**$0.00**	
TOTAL FEES ENCLOSED =				**$1,142.00**	
				Amount to be: refunded	$
				charged	$

a. ☒ A check in the amount of **$1,142.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **13-2855** A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jeffrey S. Sharp
Customer No.: 04743
MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
United States of America

SIGNATURE

Jeffrey S. Sharp
NAME

31,879
REGISTRATION NUMBER

20 December 2001
DATE

PATENT
Attorney Docket No.: 27656/38053

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **HAFEN, Ernst**

U.S. National Phase of PCT/IB99/01166 filed 22 June 1999

Filed: Herewith

For: **IN VIVO INSECT MODEL SYSTEM FOR TYPE-2 DIABETES**

Group Art Unit: Unassigned

Examiner: Unassigned

Attorney Docket No. 27656/35053

I hereby certify that this paper is being deposited with the United States Postal Service on **December 20, 2001**, in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service under Mailing Label No. **EK 657 819 788 US**.

December 20, 2001

Richard Zimmermann

STATEMENT UNDER 37 C.F.R. §§1.821(f)

BOX PCT
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted herewith in accordance with 37 C.F.R. §§1.821 and 1.825, are the same.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

By

Jeffrey S. Sharp
Registration No. 31,879
Attorney for Applicants

December 20, 2001

SEQUENCE LISTING

<110> HAFEN, Ernst

<120> In vivo model system for type-2 diabetes

<130> 27656/38053

<140> To be determined
<141> To be determined

<150> PCT/IB99/01166
<151> 1999-06-22

<160> 4

<170> PatentIn Ver. 2.1

<210> 1
<211> 2907
<212> DNA
<213> Drosophila melanogaster

<400> 1
atggcatcaa tatcggatga cggcatggcg ctgagtggct acctcaagaa gctgaagacc 60

atgaagaaga agttctttgt gctgtacgag gagacgagca cttcggcagc ccggctggag 120

tactacgata ccgaaaagaa gttcctgcaa agagccgagc caaaaagggt tatatatctg 180

aagaattgct tcaacatcaa tcgccgtttg gacaccaagc atagatttgt cattgtgctc 240

tcctccagag acggtggatt cggcatcgtt ctcgagaacg aaaatgattt acgcaaatgg 300

ttggacaaac tactagttct acaaaggaac atagccaatt cgaatggaac agcgcactca 360

ccttatgacc acgtttggca agttgtcatt caaaagaagg gtatttcgga gaaagttgga 420

atcaccggaa cctaccactg ttgccttact tcaaaatccc tgacattcgt gtgcattgga 480

ccggagaaga cgcccaatgg cgaggatcgc gttgcgagca ttgaaatact tttgaccacg 540

atcaggcgat gcggtcatgc atccccacaa tgtatattct acgtggaact tggccgccaa 600

agtgtcttgg gatctggtga tctgtggatg gagacggata acgcagctat tgctactaat 660

atgcacaaca cgatactgag cgctatgtca gccaaaacag agtcgaacac gaatttaata 720

aacgtttatc agaatagacc tgacttaagt cacgagccca tgagaaagcg atcgtcgtct 780

gcaaacgaag catcgaagcc gataaacgta aatgtcatac aaaatagtca aaactctctc 840

gaattgcgca gctgcagttc gccccataac tatggtttcg gcagagagag atgcgatagc 900

ttaccaacca gaaatggaac cctaagcgag tccagcaatc aaacgtactt tggttccaac 960

catggactgc gatccaatac tatatctggc atccgtccgc actcaaccaa caagcatagt 1020

aatagtccaa cgttcaccat gccattaaga tgctcagaat ccgaagagtc atcaattagt 1080

gtcgatgaat ccgacgacaa cggcagtttt agccactaca gattaaacac gcggtcatct 1140

gagacggcaa ttcctgagga aaacattgat gactttgcca gtgcggaatt atttagcaaa 1200

gtcaccgaac aaaatgtaag tgacgaaaac tacataccga tgaatccagt caatcctacc 1260

gatgctatcc atgaaaagga gaaggctgat atgcagagat tggaagatgc ttcgctgcat 1320

ttcaactttc cggagcacgc gtcggaaaag cttgctaagg attttgatct ggactctgat 1380

aaccaatgct gtcgtcccat tcgcgcctat tcgataggca acaaggttga gcatttaaag 1440

tttaataagc gcctgggaca cttgaatgat acgggacaga atccgaatcg cgtgcgagcc 1500

tactcggttg gctccaaatc gaagataccg cgctgcgacc tgcagcgagt ggtcctcgtg 1560

gaggacaata aacatgagtt cacagcgaat aggagtcaga gtagcattac caaggaagga 1620

accagctatg gcagcagtgc caatcgacaa aagaagtcca caagtgctcc actcctcagt 1680

ctgaagaacc agataaactc cgaccgaatg agtgacttaa tggaaattga tttttcacaa 1740

gcaaccaatt tggaaaagca gaagttcatc aagaataatg aaattccgaa atacattgaa 1800

aacgtgttcc caaaagcccc gcgaacggat agctccagcc taactctgca cgccacaagt 1860

caaaaggaca ttttcaatgg caccaaacta aataacactg cgatcacatc cgaggatggt 1920

tacctcgaga tgaagccagt cggtaatgga tacactccca gttcgaattg cctgccaatg 1980

aaagtggaga aactcaagct atccgactat cagacagcac cgccactcac cgcaacagcc 2040

gcaccagtgc acgatttaaa caaaattagc acatacaata tatccgctga gaaatggaga 2100

gaacagccca gcagaagcga ggaaaagaag tcgaactcgc cattgaatga caacaccttt 2160

agctcgaaac ccacaaatgt cgagagtaca agcaaaagcc atgatgttca ttcagcaaat 2220

caaattgatt gcgagaaagt gtgcgcgcag agcagcgata agctaaataa tcatctggcc 2280

gacaagattg tcgagaacaa caatttggat ataggcgggc atgaggaaaa gaagttggtt 2340

cattcgataa gcagcgaaga ctacacacaa atcaaggaca aatcgaatga tttcacaaaa 2400

tttaacgaag ccggctacaa aattctgcaa attaaaagcg acagctcact catctcatcg 2460

aagctatacc aaaagggtat acacaaggat aacttggagc gttcgcagag acttacagag 2520

agtgtgaata cgattcccga taatgccacc gccaccgcgg tgagcagcag ctcactcacc 2580

aaattcaata taaattcagc aaagccagcc gccgccgccg attcgcgtag cactggcaca 2640

gatccaagta caccacagaa cattctacag attaaagatt tgaatttccc ctcaaggtcg 2700

tcgtctcgca tatcccagcc ggagctgcac tacgccagcc tagatcttcc ccattgcagt 2760

ggccaaaatc cagctaaata cctgaagaga ggatcacgcg aatcgccgcc ggtgtccgca 2820

tgcccggagg atgggaatac ctatgcgaaa atcgactttg accaatccga ctcctcttcc 2880

tcctcatcga acatatttaa tacgtaa 2907

<210> 2
<211> 2907
<212> DNA
<213> Drosophila melanogaster

<220>
<221> CDS
<222> (1)..(2907)

<400> 2

```
atg gca tca ata tcg gat gac ggc atg gcg ctg agt ggc tac ctc aag   48
Met Ala Ser Ile Ser Asp Asp Gly Met Ala Leu Ser Gly Tyr Leu Lys
  1               5                  10                  15

aag ctg aag acc atg aag aag aag ttc ttt gtg ctg tac gag gag acg   96
Lys Leu Lys Thr Met Lys Lys Lys Phe Phe Val Leu Tyr Glu Glu Thr
            20                  25                  30

agc act tcg gca gcc cgg ctg gag tac tac gat acc gaa aag aag ttc  144
Ser Thr Ser Ala Ala Arg Leu Glu Tyr Tyr Asp Thr Glu Lys Lys Phe
        35                  40                  45

ctg caa aga gcc gag cca aaa agg gtt ata tat ctg aag aat tgc ttc  192
Leu Gln Arg Ala Glu Pro Lys Arg Val Ile Tyr Leu Lys Asn Cys Phe
    50                  55                  60

aac atc aat cgc cgt ttg gac acc aag cat aga ttt gtc att gtg ctc  240
Asn Ile Asn Arg Arg Leu Asp Thr Lys His Arg Phe Val Ile Val Leu
65                  70                  75                  80

tcc tcc aga gac ggt gga ttc ggc atc gtt ctc gag aac gaa aat gat  288
Ser Ser Arg Asp Gly Gly Phe Gly Ile Val Leu Glu Asn Glu Asn Asp
                85                  90                  95

tta cgc aaa tgg ttg gac aaa cta cta gtt cta caa agg aac ata gcc  336
Leu Arg Lys Trp Leu Asp Lys Leu Leu Val Leu Gln Arg Asn Ile Ala
            100                 105                 110

aat tcg aat gga aca gcg cac tca cct tat gac cac gtt tgg caa gtt  384
Asn Ser Asn Gly Thr Ala His Ser Pro Tyr Asp His Val Trp Gln Val
        115                 120                 125

gtc att caa aag aag ggt att tcg gag aaa gtt gga atc acc gga acc  432
Val Ile Gln Lys Lys Gly Ile Ser Glu Lys Val Gly Ile Thr Gly Thr
    130                 135                 140

tac cac tgt tgc ctt act tca aaa tcc ctg aca ttc gtg tgc att gga  480
Tyr His Cys Cys Leu Thr Ser Lys Ser Leu Thr Phe Val Cys Ile Gly
145                 150                 155                 160

ccg gag aag acg ccc aat ggc gag gat cgc gtt gcg agc att gaa ata  528
Pro Glu Lys Thr Pro Asn Gly Glu Asp Arg Val Ala Ser Ile Glu Ile
                165                 170                 175

ctt ttg acc acg atc agg cga tgc ggt cat gca tcc cca caa tgt ata  576
Leu Leu Thr Thr Ile Arg Arg Cys Gly His Ala Ser Pro Gln Cys Ile
            180                 185                 190

ttc tac gtg gaa ctt ggc cgc caa agt gtc ttg gga tct ggt gat ctg  624
Phe Tyr Val Glu Leu Gly Arg Gln Ser Val Leu Gly Ser Gly Asp Leu
        195                 200                 205
```

```
tgg atg gag acg gat aac gca gct att gct act aat atg cac aac acg   672
Trp Met Glu Thr Asp Asn Ala Ala Ile Ala Thr Asn Met His Asn Thr
    210                 215                 220

ata ctg agc gct atg tca gcc aaa aca gag tcg aac acg aat tta ata   720
Ile Leu Ser Ala Met Ser Ala Lys Thr Glu Ser Asn Thr Asn Leu Ile
225                 230                 235                 240

aac gtt tat cag aat aga cct gac tta agt cac gag ccc atg aga aag   768
Asn Val Tyr Gln Asn Arg Pro Asp Leu Ser His Glu Pro Met Arg Lys
                245                 250                 255

cga tcg tcg tct gca aac gaa gca tcg aag ccg ata aac gta aat gtc   816
Arg Ser Ser Ser Ala Asn Glu Ala Ser Lys Pro Ile Asn Val Asn Val
            260                 265                 270

ata caa aat agt caa aac tct ctc gaa ttg cgc agc tgc agt tcg ccc   864
Ile Gln Asn Ser Gln Asn Ser Leu Glu Leu Arg Ser Cys Ser Ser Pro
        275                 280                 285

cat aac tat ggt ttc ggc aga gag aga tgc gat agc tta cca acc aga   912
His Asn Tyr Gly Phe Gly Arg Glu Arg Cys Asp Ser Leu Pro Thr Arg
    290                 295                 300

aat gga acc cta agc gag tcc agc aat caa acg tac ttt ggt tcc aac   960
Asn Gly Thr Leu Ser Glu Ser Ser Asn Gln Thr Tyr Phe Gly Ser Asn
305                 310                 315                 320

cat gga ctg cga tcc aat act ata tct ggc atc cgt ccg cac tca acc  1008
His Gly Leu Arg Ser Asn Thr Ile Ser Gly Ile Arg Pro His Ser Thr
                325                 330                 335

aac aag cat agt aat agt cca acg ttc acc atg cca tta aga tgc tca  1056
Asn Lys His Ser Asn Ser Pro Thr Phe Thr Met Pro Leu Arg Cys Ser
            340                 345                 350

gaa tcc gaa gag tca tca att agt gtc gat gaa tcc gac gac aac ggc  1104
Glu Ser Glu Glu Ser Ser Ile Ser Val Asp Glu Ser Asp Asp Asn Gly
        355                 360                 365

agt ttt agc cac tac aga tta aac acg cgg tca tct gag acg gca att  1152
Ser Phe Ser His Tyr Arg Leu Asn Thr Arg Ser Ser Glu Thr Ala Ile
    370                 375                 380

cct gag gaa aac att gat gac ttt gcc agt gcg gaa tta ttt agc aaa  1200
Pro Glu Glu Asn Ile Asp Asp Phe Ala Ser Ala Glu Leu Phe Ser Lys
385                 390                 395                 400

gtc acc gaa caa aat gta agt gac gaa aac tac ata ccg atg aat cca  1248
Val Thr Glu Gln Asn Val Ser Asp Glu Asn Tyr Ile Pro Met Asn Pro
                405                 410                 415

gtc aat cct acc gat gct atc cat gaa aag gag aag gct gat atg cag  1296
Val Asn Pro Thr Asp Ala Ile His Glu Lys Glu Lys Ala Asp Met Gln
            420                 425                 430

aga ttg gaa gat gct tcg ctg cat ttc aac ttt ccg gag cac gcg tcg  1344
Arg Leu Glu Asp Ala Ser Leu His Phe Asn Phe Pro Glu His Ala Ser
        435                 440                 445

gaa aag ctt gct aag gat ttt gat ctg gac tct gat aac caa tgc tgt  1392
Glu Lys Leu Ala Lys Asp Phe Asp Leu Asp Ser Asp Asn Gln Cys Cys
    450                 455                 460
```

```
cgt ccc att cgc gcc tat tcg ata ggc aac aag gtt gag cat tta aag   1440
Arg Pro Ile Arg Ala Tyr Ser Ile Gly Asn Lys Val Glu His Leu Lys
465                 470                 475                 480

ttt aat aag cgc ctg gga cac ttg aat gat acg gga cag aat ccg aat   1488
Phe Asn Lys Arg Leu Gly His Leu Asn Asp Thr Gly Gln Asn Pro Asn
                485                 490                 495

cgc gtg cga gcc tac tcg gtt ggc tcc aaa tcg aag ata ccg cgc tgc   1536
Arg Val Arg Ala Tyr Ser Val Gly Ser Lys Ser Lys Ile Pro Arg Cys
            500                 505                 510

gac ctg cag cga gtg gtc ctc gtg gag gac aat aaa cat gag ttc aca   1584
Asp Leu Gln Arg Val Val Leu Val Glu Asp Asn Lys His Glu Phe Thr
        515                 520                 525

gcg aat agg agt cag agt agc att acc aag gaa gga acc agc tat ggc   1632
Ala Asn Arg Ser Gln Ser Ser Ile Thr Lys Glu Gly Thr Ser Tyr Gly
    530                 535                 540

agc agt gcc aat cga caa aag aag tcc aca agt gct cca ctc ctc agt   1680
Ser Ser Ala Asn Arg Gln Lys Lys Ser Thr Ser Ala Pro Leu Leu Ser
545                 550                 555                 560

ctg aag aac cag ata aac tcc gac cga atg agt gac tta atg gaa att   1728
Leu Lys Asn Gln Ile Asn Ser Asp Arg Met Ser Asp Leu Met Glu Ile
                565                 570                 575

gat ttt tca caa gca acc aat ttg gaa aag cag aag ttc atc aag aat   1776
Asp Phe Ser Gln Ala Thr Asn Leu Glu Lys Gln Lys Phe Ile Lys Asn
            580                 585                 590

aat gaa att ccg aaa tac att gaa aac gtg ttc cca aaa gcc ccg cga   1824
Asn Glu Ile Pro Lys Tyr Ile Glu Asn Val Phe Pro Lys Ala Pro Arg
        595                 600                 605

acg gat agc tcc agc cta act ctg cac gcc aca agt caa aag gac att   1872
Thr Asp Ser Ser Ser Leu Thr Leu His Ala Thr Ser Gln Lys Asp Ile
    610                 615                 620

ttc aat ggc acc aaa cta aat aac act gcg atc aca tcc gag gat ggt   1920
Phe Asn Gly Thr Lys Leu Asn Asn Thr Ala Ile Thr Ser Glu Asp Gly
625                 630                 635                 640

tac ctc gag atg aag cca gtc ggt aat gga tac act ccc agt tcg aat   1968
Tyr Leu Glu Met Lys Pro Val Gly Asn Gly Tyr Thr Pro Ser Ser Asn
                645                 650                 655

tgc ctg cca atg aaa gtg gag aaa ctc aag cta tcc gac tat cag aca   2016
Cys Leu Pro Met Lys Val Glu Lys Leu Lys Leu Ser Asp Tyr Gln Thr
            660                 665                 670

gca ccg cca ctc acc gca aca gcc gca cca gtg cac gat tta aac aaa   2064
Ala Pro Pro Leu Thr Ala Thr Ala Ala Pro Val His Asp Leu Asn Lys
        675                 680                 685

att agc aca tac aat ata tcc gct gag aaa tgg aga gaa cag ccc agc   2112
Ile Ser Thr Tyr Asn Ile Ser Ala Glu Lys Trp Arg Glu Gln Pro Ser
    690                 695                 700

aga agc gag gaa aag aag tcg aac tcg cca ttg aat gac aac acc ttt   2160
Arg Ser Glu Glu Lys Lys Ser Asn Ser Pro Leu Asn Asp Asn Thr Phe
705                 710                 715                 720
```

```
agc tcg aaa ccc aca aat gtc gag agt aca agc aaa agc cat gat gtt   2208
Ser Ser Lys Pro Thr Asn Val Glu Ser Thr Ser Lys Ser His Asp Val
                725                 730                 735

cat tca gca aat caa att gat tgc gag aaa gtg tgc gcg cag agc agc   2256
His Ser Ala Asn Gln Ile Asp Cys Glu Lys Val Cys Ala Gln Ser Ser
            740                 745                 750

gat aag cta aat aat cat ctg gcc gac aag att gtc gag aac aac aat   2304
Asp Lys Leu Asn Asn His Leu Ala Asp Lys Ile Val Glu Asn Asn Asn
        755                 760                 765

ttg gat ata ggc ggg cat gag gaa aag aag ttg gtt cat tcg ata agc   2352
Leu Asp Ile Gly Gly His Glu Glu Lys Lys Leu Val His Ser Ile Ser
    770                 775                 780

agc gaa gac tac aca caa atc aag gac aaa tcg aat gat ttc aca aaa   2400
Ser Glu Asp Tyr Thr Gln Ile Lys Asp Lys Ser Asn Asp Phe Thr Lys
785                 790                 795                 800

ttt aac gaa gcc ggc tac aaa att ctg caa att aaa agc gac agc tca   2448
Phe Asn Glu Ala Gly Tyr Lys Ile Leu Gln Ile Lys Ser Asp Ser Ser
                805                 810                 815

ctc atc tca tcg aag cta tac caa aag ggt ata cac aag gat aac ttg   2496
Leu Ile Ser Ser Lys Leu Tyr Gln Lys Gly Ile His Lys Asp Asn Leu
            820                 825                 830

gag cgt tcg cag aga ctt aca gag agt gtg aat acg att ccc gat aat   2544
Glu Arg Ser Gln Arg Leu Thr Glu Ser Val Asn Thr Ile Pro Asp Asn
        835                 840                 845

gcc acc gcc acc gcg gtg agc agc agc tca ctc acc aaa ttc aat ata   2592
Ala Thr Ala Thr Ala Val Ser Ser Ser Ser Leu Thr Lys Phe Asn Ile
    850                 855                 860

aat tca gca aag cca gcc gcc gcc gcc gat tcg cgt agc act ggc aca   2640
Asn Ser Ala Lys Pro Ala Ala Ala Ala Asp Ser Arg Ser Thr Gly Thr
865                 870                 875                 880

gat cca agt aca cca cag aac att cta cag att aaa gat ttg aat ttc   2688
Asp Pro Ser Thr Pro Gln Asn Ile Leu Gln Ile Lys Asp Leu Asn Phe
                885                 890                 895

ccc tca agg tcg tcg tct cgc ata tcc cag ccg gag ctg cac tac gcc   2736
Pro Ser Arg Ser Ser Ser Arg Ile Ser Gln Pro Glu Leu His Tyr Ala
            900                 905                 910

agc cta gat ctt ccc cat tgc agt ggc caa aat cca gct aaa tac ctg   2784
Ser Leu Asp Leu Pro His Cys Ser Gly Gln Asn Pro Ala Lys Tyr Leu
        915                 920                 925

aag aga gga tca cgc gaa tcg ccg ccg gtg tcc gca tgc ccg gag gat   2832
Lys Arg Gly Ser Arg Glu Ser Pro Pro Val Ser Ala Cys Pro Glu Asp
    930                 935                 940

ggg aat acc tat gcg aaa atc gac ttt gac caa tcc gac tcc tct tcc   2880
Gly Asn Thr Tyr Ala Lys Ile Asp Phe Asp Gln Ser Asp Ser Ser Ser
945                 950                 955                 960

tcc tca tcg aac ata ttt aat acg taa                              2907
Ser Ser Ser Asn Ile Phe Asn Thr
                965
```

<210> 3
<211> 968
<212> PRT
<213> Drosophila melanogaster

<400> 3

```
Met Ala Ser Ile Ser Asp Asp Gly Met Ala Leu Ser Gly Tyr Leu Lys
  1               5                  10                  15

Lys Leu Lys Thr Met Lys Lys Lys Phe Phe Val Leu Tyr Glu Glu Thr
             20                  25                  30

Ser Thr Ser Ala Ala Arg Leu Glu Tyr Tyr Asp Thr Glu Lys Lys Phe
         35                  40                  45

Leu Gln Arg Ala Glu Pro Lys Arg Val Ile Tyr Leu Lys Asn Cys Phe
     50                  55                  60

Asn Ile Asn Arg Arg Leu Asp Thr Lys His Arg Phe Val Ile Val Leu
 65                  70                  75                  80

Ser Ser Arg Asp Gly Gly Phe Gly Ile Val Leu Glu Asn Glu Asn Asp
                 85                  90                  95

Leu Arg Lys Trp Leu Asp Lys Leu Leu Val Leu Gln Arg Asn Ile Ala
            100                 105                 110

Asn Ser Asn Gly Thr Ala His Ser Pro Tyr Asp His Val Trp Gln Val
        115                 120                 125

Val Ile Gln Lys Lys Gly Ile Ser Glu Lys Val Gly Ile Thr Gly Thr
    130                 135                 140

Tyr His Cys Cys Leu Thr Ser Lys Ser Leu Thr Phe Val Cys Ile Gly
145                 150                 155                 160

Pro Glu Lys Thr Pro Asn Gly Glu Asp Arg Val Ala Ser Ile Glu Ile
                165                 170                 175

Leu Leu Thr Thr Ile Arg Arg Cys Gly His Ala Ser Pro Gln Cys Ile
            180                 185                 190

Phe Tyr Val Glu Leu Gly Arg Gln Ser Val Leu Gly Ser Gly Asp Leu
        195                 200                 205

Trp Met Glu Thr Asp Asn Ala Ala Ile Ala Thr Asn Met His Asn Thr
    210                 215                 220

Ile Leu Ser Ala Met Ser Ala Lys Thr Glu Ser Asn Thr Asn Leu Ile
225                 230                 235                 240

Asn Val Tyr Gln Asn Arg Pro Asp Leu Ser His Glu Pro Met Arg Lys
                245                 250                 255

Arg Ser Ser Ser Ala Asn Glu Ala Ser Lys Pro Ile Asn Val Asn Val
            260                 265                 270

Ile Gln Asn Ser Gln Asn Ser Leu Glu Leu Arg Ser Cys Ser Ser Pro
        275                 280                 285

His Asn Tyr Gly Phe Gly Arg Glu Arg Cys Asp Ser Leu Pro Thr Arg
    290                 295                 300
```

Asn Gly Thr Leu Ser Glu Ser Ser Asn Gln Thr Tyr Phe Gly Ser Asn
305 310 315 320

His Gly Leu Arg Ser Asn Thr Ile Ser Gly Ile Arg Pro His Ser Thr
325 330 335

Asn Lys His Ser Asn Ser Pro Thr Phe Thr Met Pro Leu Arg Cys Ser
340 345 350

Glu Ser Glu Glu Ser Ser Ile Ser Val Asp Glu Ser Asp Asp Asn Gly
355 360 365

Ser Phe Ser His Tyr Arg Leu Asn Thr Arg Ser Ser Glu Thr Ala Ile
370 375 380

Pro Glu Glu Asn Ile Asp Asp Phe Ala Ser Ala Glu Leu Phe Ser Lys
385 390 395 400

Val Thr Glu Gln Asn Val Ser Asp Glu Asn Tyr Ile Pro Met Asn Pro
405 410 415

Val Asn Pro Thr Asp Ala Ile His Glu Lys Glu Lys Ala Asp Met Gln
420 425 430

Arg Leu Glu Asp Ala Ser Leu His Phe Asn Phe Pro Glu His Ala Ser
435 440 445

Glu Lys Leu Ala Lys Asp Phe Asp Leu Asp Ser Asp Asn Gln Cys Cys
450 455 460

Arg Pro Ile Arg Ala Tyr Ser Ile Gly Asn Lys Val Glu His Leu Lys
465 470 475 480

Phe Asn Lys Arg Leu Gly His Leu Asn Asp Thr Gly Gln Asn Pro Asn
485 490 495

Arg Val Arg Ala Tyr Ser Val Gly Ser Lys Ser Lys Ile Pro Arg Cys
500 505 510

Asp Leu Gln Arg Val Val Leu Val Glu Asp Asn Lys His Glu Phe Thr
515 520 525

Ala Asn Arg Ser Gln Ser Ser Ile Thr Lys Glu Gly Thr Ser Tyr Gly
530 535 540

Ser Ser Ala Asn Arg Gln Lys Lys Ser Thr Ser Ala Pro Leu Leu Ser
545 550 555 560

Leu Lys Asn Gln Ile Asn Ser Asp Arg Met Ser Asp Leu Met Glu Ile
565 570 575

Asp Phe Ser Gln Ala Thr Asn Leu Glu Lys Gln Lys Phe Ile Lys Asn
580 585 590

Asn Glu Ile Pro Lys Tyr Ile Glu Asn Val Phe Pro Lys Ala Pro Arg
595 600 605

Thr Asp Ser Ser Ser Leu Thr Leu His Ala Thr Ser Gln Lys Asp Ile
610 615 620

Phe Asn Gly Thr Lys Leu Asn Asn Thr Ala Ile Thr Ser Glu Asp Gly
625 630 635 640

Tyr Leu Glu Met Lys Pro Val Gly Asn Gly Tyr Thr Pro Ser Ser Asn
645 650 655

Cys Leu Pro Met Lys Val Glu Lys Leu Lys Leu Ser Asp Tyr Gln Thr
660 665 670

Ala Pro Pro Leu Thr Ala Thr Ala Ala Pro Val His Asp Leu Asn Lys
675 680 685

Ile Ser Thr Tyr Asn Ile Ser Ala Glu Lys Trp Arg Glu Gln Pro Ser
690 695 700

Arg Ser Glu Glu Lys Lys Ser Asn Ser Pro Leu Asn Asp Asn Thr Phe
705 710 715 720

Ser Ser Lys Pro Thr Asn Val Glu Ser Thr Ser Lys Ser His Asp Val
725 730 735

His Ser Ala Asn Gln Ile Asp Cys Glu Lys Val Cys Ala Gln Ser Ser
740 745 750

Asp Lys Leu Asn Asn His Leu Ala Asp Lys Ile Val Glu Asn Asn Asn
755 760 765

Leu Asp Ile Gly Gly His Glu Glu Lys Lys Leu Val His Ser Ile Ser
770 775 780

Ser Glu Asp Tyr Thr Gln Ile Lys Asp Lys Ser Asn Asp Phe Thr Lys
785 790 795 800

Phe Asn Glu Ala Gly Tyr Lys Ile Leu Gln Ile Lys Ser Asp Ser Ser
805 810 815

Leu Ile Ser Ser Lys Leu Tyr Gln Lys Gly Ile His Lys Asp Asn Leu
820 825 830

Glu Arg Ser Gln Arg Leu Thr Glu Ser Val Asn Thr Ile Pro Asp Asn
835 840 845

Ala Thr Ala Thr Ala Val Ser Ser Ser Ser Leu Thr Lys Phe Asn Ile
850 855 860

Asn Ser Ala Lys Pro Ala Ala Ala Ala Asp Ser Arg Ser Thr Gly Thr
865 870 875 880

Asp Pro Ser Thr Pro Gln Asn Ile Leu Gln Ile Lys Asp Leu Asn Phe
885 890 895

Pro Ser Arg Ser Ser Ser Arg Ile Ser Gln Pro Glu Leu His Tyr Ala
900 905 910

Ser Leu Asp Leu Pro His Cys Ser Gly Gln Asn Pro Ala Lys Tyr Leu
915 920 925

Lys Arg Gly Ser Arg Glu Ser Pro Pro Val Ser Ala Cys Pro Glu Asp
930 935 940

Gly Asn Thr Tyr Ala Lys Ile Asp Phe Asp Gln Ser Asp Ser Ser Ser
945 950 955 960

Ser Ser Ser Asn Ile Phe Asn Thr
965

<210> 4
<211> 5210
<212> DNA
<213> Drosophila melanogaster

<400> 4
agaacgactt tttcctcctt agtcagtcac aagaaaacta aagcttacca acaatacggc 60

gtgtattgtt aaattattac aacaaataaa atattcaaat tgtatttaaa aatatagtaa 120

ccattaaaaa ataaaatcaa tatgcgaaac tttgtaattt cttactcatc cttgtttttt 180

gagcccgctt tcttaagtta aatcgttaaa ataccagttt aatcatttca ttgtcctgat 240

ttcaggagct aattacattt taatctttgt ataaattcat aaaattaaaa tggaaatgtt 300

taaccacata aaatatttgg gtatataaag tcgatacata cttttaaaat tttgtttcat 360

acaagaatat ggaaagtaga taatttagtt accgattaaa acatttctaa aatacaaaaa 420

atttaaaatg atgattaaat aaaaaactgt tatactaaat ttaaacgaaa caaacggtca 480

ttcgataact caattagtat cgaataagcc ggcgtgtaaa tcgggttggc aactctcacc 540

ggtgtagaga tcgggatggc aacttcgtat tgttattcct atgctgcgat aacgataaca 600

gcaaagtgtc atcgcgaata aatgtgggtt tgataataaa gaattgcgtt ggtgaacaat 660

aataatacaa atgctaaatg tatcgcgcgg ataactagta aacactgatt tcgcgcatat 720

cgggcatacg ggcagctaga cgtcttaggt aacacatttc ccagccacat tggcgttgag 780

gtattatttc ccatatccat gtgcgtttgt aaatgatacc accagagtgt gccatatgta 840

tcgttgtttg tacatacatg cctacgggga aaaataactc gcagatacat atgtatgtaa 900

gatgtattag aattccacag atatatgtac atataaatat atatatatat ttatgatgct 960

catctataaa acaaaatatg tacaaacata cgcgcgcacg tacttatgta tgtacatata 1020

catatataca tatatgtata ataaaatgag catctagctg cggttatctt aatgcaatgc 1080

gcagaaacct gaaaacgaaa taaacaatct ttacagcgcc agcacagtga gccaattatg 1140

aattcacaat tccacatcca attccgattc cgaattccat cgctttacat cctaattcga 1200

atacgtcgcg ccgcgtaagc tgcactcgaa tattgacata aacgacgtaa ttgcgtgttt 1260

tgattgcgat ttccgatgct cgatgttgac agacggcaag gatttttttt gccagccgac 1320

attgcgaatg cttttcgcgt gtttgcgttg tgaaaagcga tttgttgttc cggcagttgg 1380

aaatgttttg tgctgtttat gcttagaaaa gcaaatgtat tgcacaaaac tcgtgtttcc 1440

tacattagta aagcctataa cttaggtata tgtttctaaa ttacaatgca aaaaataaaa 1500

aacattatac atgtgttcgt tctttaattt gaaaacagaa aagtgaaagc cttgcaaatc 1560

aaatatgtgt ccatatcgcc tactaataat ataaacacgt cgccttccag gaactaagat 1620

tggaaatcat ggcatcaata tcggatgacg gcatggcgct gagtggctac ctcaagaagc 1680

tgaagaccat gaagaagaag ttctttgtgc tgtacgagga gacgagcact tcggcagccc 1740

ggctggagta ctacgatacc gaaaagaagt tcctgcaaag agccgagcca aaaagggtta 1800

tctatctgaa gaattgcttc aacatcaatc gccgtttgga caccaagcat agatttgtca 1860

ttgtgctctc ctccagagac ggtggattcg gcatcgttct cgagaacgaa aatgatttac 1920

gcaaatggtt ggacaaacta ctagttctac aaaggaacat agccaattcg aatggaacag 1980

cgcactcacc ttatggtatg ccaaataaac tataactacc agttagtatg aaacctaaac 2040

acttcatttc actttgcaga ccacgtttgg caagttgtca ttcaaaagaa gggtatttcg 2100

gagaaagttg gaatcaccgg aacctaccac tgttgcctta cttcaaaatc cctgacattc 2160

gtgtgcattg gaccggagaa gacgcccaat ggcgaggatc gcgttgcgag cattgaaata 2220

cttttgacca cgatcaggcg gttagttgtt gccagcaaaa ctgcaaggga ttgtaaaata 2280

attcggactt aatttcagat gcggtcatgc atccccacaa tgtatattct acgtggaact 2340

tggccgccaa agtgtcttgg gatctggtga tctgtggatg gagacggata acgcagctat 2400

tgctactaat atgcacaaca cgatactgag gtatttagct ctcattacaa ctaatccaag 2460

atttcatgat catcctacaa aacgacatag atagtttaag atatctccca gttaacttta 2520

ataattctgt gggtttttc tttcagcgct atgtcagcca aaacagagtc gaacacgaat 2580

ttaataaacg tttatcagaa cagacctgac ttaagtcacg agcccatgag aaagcgatcg 2640

tcgtctgcaa acgaagcatc gaagccgata aacgtaaatg tcatacaaaa tagtcaaaac 2700

tctctcgaat tgcgcagctg cagttcgccc cataactatg gtaaatactt caaatgtatg 2760

tttaaacgca aaattaatca aacgcaatcg tttcaggttt cggcagagag agatgcgata 2820

gcttaccaac cagaaatgga accctaagcg agtccagcaa tcaaacgtac tttggttcca 2880

accatggact gcgatccaat actatatctg gcatccgtcc gcactcaacc aacaagcata 2940

gtaatagtcc aacgttcacc atgccattaa gatgctcaga atccgaagag tcatcaatta 3000

gtgtcgatga atccgacgac aacggcagtt ttagccacta cagattaaag tgcgttgcta 3060

tcaaataata attatttaat aataatcacc atttcaattt ctagcacgcg gtcatctgag 3120

acggcaattc ctgaggaaaa cattgatgac tttgccagtg cggaattatt tagcaaagtc 3180

accgaacaaa atggtaagcc aaacacaaaa acaatttttt aacatgaaaa gtagctaatc 3240

aattggcttt gtttaactgc agtaagtgac gaaaactaca taccgatgaa tccagtcaat 3300

cctaccgatg ctatccatga aaaggagaag gctgatatgc agagattgga agatgcttcg 3360

ctgcatttca actttccgga gcacgcgtcg gaaaagcttg ctaaggattt tgatctggac 3420

tctgataacc agtgagtaca catttcgctt caactgtgcc acgtaatgca atcaatcaca 3480

tcttgttaca gatgctgtcg tcccattcgc gcctattcga taggcaacaa ggttgagcat 3540

ttaaagttta ataagcgcct gggacacttg aatgatacgg gacagaatcc gaatcgcgtg 3600

cgagcctact cggttggctc caaatcgaag ataccgcgct gcgacctgca gcgagtggtc 3660

ctcgtggagg acaataaaca tgagttcaca gcgaatagga gtcagagtag cattaccaag 3720

gaaggaacca gctatggcag cagtgccaat cgacaaaaga agtccacaag tgctccactc 3780

ctcagtctga agaaccagat aaactccgac cgaatgagtg acttaatgga aattgatttt 3840

tcacaagcaa ccaatttgga aaagcagaag ttcatcaaga ataatgaaat tccgaaatac 3900

attgaaaacg tgttcccaaa agccccgcga acggatagct ccagcctaac tctgcacgcc 3960

acaagtcaaa aggacatttt caatggcacc aaactaaata acactgcgat cacatccgag 4020

gatggttacc tcgagatgaa gccagtcggt aatggataca ctcccagttc gaattgcctg 4080

ccaatgaaag tggagaggct caagctatcc gactatcaga cagcaccgcc aatcaccgca 4140

acagccgcac cagtgcacga tttaaacaaa attagcacat acaatatatc cgctgagaaa 4200

tggagagaac agcccagcag aagcgaggaa aagaagtcga actcgccatt gaatgacaac 4260

acctttggct tgaaacccac aaatgtcgag agtacaagca aaagccatga tgttcattca 4320

gcaaatcaaa ttgattccga gaaagtgtgc gcgcagagca gcgataagct aaataatctg 4380

gccgacaaga ttgtcgagaa caacaatttg gatataggcg ggcatgagga aaagaagttg 4440

gttcattcga taagcagcga agactacaca caaatcaagg acaaatcgaa tgatttcaca 4500

aaatttaacg aagccggcta caaaattctg caaattaaaa gcgacagctc actcatctca 4560

tcgaagctat accaaaaggg tatacacaag gataacttgg agcgttcgca gagacttacg 4620

gagagtgtga atacgattcc cgataatgcc accgccaccg cggtgagcag cagctcactc 4680

accaaattca atataaattc agcaaagcca gccgccgccg ccgattcgcg tagcactggc 4740

acagatccaa gtacaccaca gaacattcta cagattaaag atttgaattt cccctcaagg 4800

tcgtcgtctc gcatatccca gccggagctg cactacgcca gcctagatct tccccattgc 4860

agtggccaaa atccagctaa atacctgaag agaggatcac gcgaatcgcc gccggtgtcc 4920

gcatgcccgg aggatgggaa tacctatgcg aaaatcgact ttgaccaatc cgactcctct 4980

tcctcctcat cgaacatatt taatacgtaa agttttgaaa tttatgaccc tatcctatat 5040

atatgatttg tttaatattg tacatttatt gtaaatattc tctgacaagc aaagcttaca 5100

attttggatg ctaataaata aattttattt aaattataat gatccctttg gacttttttt 5160

ttttttggac taagaaatca ctactaaaga agggcttttc gagggttaaa 5210

PATENT APPLICATION

IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE

Applicant: **HAFEN, Ernst**

U.S. National Phase of PCT/IB99/01166 filed 22 June 1999

Filed: Herewith

For: **IN VIVO INSECT MODEL SYSTEM FOR TYPE-2 DIABETES**

Group Art Unit: Unassigned

Examiner: Unassigned

Attorney Docket No. 27656/35053

I hereby certify that this paper is being deposited with the United States Postal Service on **December 20, 2001**, in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service under Mailing Label No. **EK 657 819 788 US**.

December 20, 2001

Richard Zimmermann

PRELIMINARY AMENDMENT ACCOMPANYING FILING
OF NATIONAL STAGE APPLICATION UNDER 35 U.S.C. 371

Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

AMENDMENT

Please amend claims 1, 4-5, 8-10, 12-14, 17-18, 21, 23, 25-31 as follows:

In the Claims:

1. [AMENDED] A method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable *chico* mutant insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size, cell size, development time or lipid level is determined whereby alterations of the body size, cell size, development time or lipid level are detectable in at least part of the animal.

4. [AMENDED] The method of claim 2 wherein the mutant does not comprise a wild-type *chico* gene.

5. [AMENDED] The method of claim 2 wherein the Drosophila mutant comprises one wild-type *chico* gene.

8. [AMENDED] The method of claim 2 wherein the Drosophila mutant comprises at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

10. [AMENDED] The method of claim 2 wherein the Drosophila lacks at least one *chico* gene.

12. [AMENDED] The method of claim 2 wherein the compound is a compound for the treatment of diabetes type 2.

13. [AMENDED] The method of claim 2 wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the whole animal.

14. [AMENDED] The method of claim 2 wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the head region only.

17. [AMENDED] The mutant of claim 15 that does not comprise a wild-type *chico* gene.

18. [AMENDED] The mutant of claim 15 that comprises one wild-type *chico* gene.

21. [AMENDED] The mutant of claim 15 comprising at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

23. [AMENDED] The mutant of claim 15 lacking at least one *chico* gene.

25. [AMENDED] The mutant of claim 15 which is a fly mutant.

26. [AMENDED] The mutant of claim 15 wherein at most one wild-type *chico* gene is found in the whole body of the insect.

27. [AMENDED] The mutant of claim 15 wherein at most one wild-type *chico* gene is found in the head region of the insect only.

28. [AMENDED] Use of an insect according to claim 15 as a means in screening compounds for modulating diseases.

29. [AMENDED] Use of an insect according to claim 15 as a means for searching for mutations involved directly or indirectly in the insulin signaling pathway.

30. [AMENDED] Use according to claim 22 characterized in that the disease is diabetes type 2.

31. [AMENDED] A method for generating a mutant insect, characterized in that adult animals are treated with a mutation generating means under mutation generating conditions, that thus treated insects are crossed to wild-type or mutant insects and that viable offsprings with altered cell number, cell size, developmental time or lipid levels are cultivated under suitable conditions.

Please add the following claims:

--32. The method of claim 31 wherein the adult animals are males.

33. The method of claim 31 wherein the treated insects are crossed with *chico* mutant insects.

34. The Mutant of claim 25 which is a Drosophila mutant.--

REMARKS

The foregoing amendments are made to change multiple dependencies. No new matter is introduced thereby and allowance of all claims 1-34 is hereby solicited.

Attached hereto as pages 6 through 9 is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned **"Version With Markings to Show Changes Made."**

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By _____

Jeffrey S. Sharp, Reg. No. 31,879
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

Chicago, Illinois
December 20, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 1, 4-5, 8-10, 12-14, 17-18, 21, 23, 25-31 have been amended as follows:

1. [AMENDED] A method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable *chico* mutant insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size, [and/or] cell size, [and/or] development time [and/] or lipid level is determined whereby alterations of the body size, [and/or] cell size, [and/or] development time [and/] or lipid level are detectable in at least part of the animal.

4. [AMENDED] The method of claim 2 [or 3] wherein the mutant does not comprise a wild-type *chico* gene.

5. [AMENDED] The method of claim 2 [or 3] wherein the Drosophila mutant comprises one wild-type *chico* gene.

8. [AMENDED] The method of claim 2 [anyone of claims 2 to 7] wherein the Drosophila mutant comprises at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

10. [AMENDED] The method of claim 2 [anyone of claims 2 to 9] wherein the Drosophila lacks at least one *chico* gene.

12. [AMENDED] The method of claim 2 [anyone of claims 1 to 11] wherein the compound is a compound for the treatment of diabetes type 2.

13. [AMENDED] The method of claim 2 [anyone of claims 1 to 12,] wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the whole animal.

14. [AMENDED] The method of claim 2 [anyone of claims 1 to 12,] wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the head region only.

17. [AMENDED] The mutant of claim 15 [or 16] that does not comprise a wild-type *chico* gene.

18. [AMENDED] The mutant of claim 15 [or 16] that comprises one wild-type *chico* gene.

21. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 20]comprising at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

23. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 22] lacking at least one *chico* gene.

25. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 24] which is a fly mutant[, in particular a Drosophila mutant].

26. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 25,] wherein at most one wild-type *chico* gene is found in the whole body of the insect.

27. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 25,] wherein at most one wild-type *chico* gene is found in the head region of the insect only.

28. [AMENDED] Use of an insect according to claim 15 [anyone of claims 15 to 27,] as a means in screening compounds for modulating diseases.

29. [AMENDED] Use of an insect according to claim 15 [anyone of claims 15 to 27] as a means for searching for mutations involved directly or indirectly in the insulin signaling pathway.

30. [AMENDED] Use according to claim 22 [or 23,] characterized in that the disease is diabetes type 2.

31. [AMENDED] A method for generating a mutant insect, characterized in that adult animals[, in particular males,] are treated with a mutation generating means under mutation generating conditions, that thus treated insects are crossed to wild-type or mutant insects[, in particular *chico* mutant insects,] and that viable offsprings with altered cell number, [and/or] cell size, [and/or] developmental time [and/]or lipid levels are cultivated under suitable conditions.

Claims 32-34 have been added as follows:

--32. The method of claim 31 wherein the adult animals are males.

33. The method of claim 31 wherein the treated insects are crossed with *chico* mutant insects.

34. The Mutant of claim 25 which is a Drosophila mutant.--

CLEAN VERSION OF CLAIMS AFTER AMENDMENT

1. A method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable *chico* mutant insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size, cell size, development time or lipid level is determined whereby alterations of the body size, cell size, development time or lipid level are detectable in at least part of the animal.

2. The method of claim 1 characterized in that the viable *chico* mutant insect comprises at most one wild-type *chico* gene.

3. The method of claim 2 wherein the mutant is a Drosophila mutant and wherein said mutant is treated in the egg or larvae stadium with said compound or compound generating means.

4. The method of claim 2 wherein the mutant does not comprise a wild-type *chico* gene.

5. The method of claim 2 wherein the Drosophila mutant comprises one wild-type *chico* gene.

6. The method of claim 5 wherein the wild-type *chico* gene encodes the amino acid sequence of Table 1 (SEQ. ID. NO. 2, 3).

7. The method of claim 6, wherein the wild-type *chico* gene is the genomic or the cDNA sequence represented in Table 1 (SEQ. ID. NO. 1, 2) or Table 2 (SEQ. ID. NO. 4).

8. The method of claim 2 wherein the Drosophila mutant comprises at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

9. The method of claim 7 wherein the *chico* mutation is the mutation described in Figure 3A.

10. The method of claim 2 wherein the Drosophila lacks at least one *chico* gene.

11. The method of claim 10 wherein the mutant lacks both *chico* genes.

12. The method of claim 2 wherein the compound is a compound for the treatment of diabetes type 2.

13. The method of claim 2 wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the whole animal.

14. The method of claim 2 wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the head region only.

15. A viable insect mutant comprising at most one wild-type *chico* gene in at least a part of its body and said at least one part of the body shows reduced size.

16. The mutant of claim 15 that does not comprise as sole *chico* genes two *chico* genes.

17. The mutant of claim 15 that does not comprise a wild-type *chico* gene.

18. The mutant of claim 15 that comprises one wild-type *chico* gene.

19. The mutant of claim 18 wherein the wild-type *chico* gene encodes the amino acid sequence of Table 1 (SEQ. ID. NO. 2, 3).

20. The mutant of claim 19, wherein the wild-type *chico* gene is the genomic or the cDNA sequence represented in Table 2 (SEQ. ID NO. 4) or Table 1 (SEQ. ID. NO. 1, 2).

21. The mutant of claim 15 comprising at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

22. The mutant of claim 21 wherein the *chico* mutation is the mutation described in Figure 3A.

23. The mutant of claim 15 lacking at least one *chico* gene.

24. The mutant of claim 15 lacking both *chico* genes.

25. The mutant of claim 15 which is a fly mutant.

26. The mutant of claim 15 wherein at most one wild-type *chico* gene is found in the whole body of the insect.

27. The mutant of claim 15 wherein at most one wild-type *chico* gene is found in the head region of the insect only.

28. Use of an insect according to claim 15 as a means in screening compounds for modulating diseases.

29. Use of an insect according to claim 15 as a means for searching for mutations involved directly or indirectly in the insulin signaling pathway.

30. Use according to claim 22 characterized in that the disease is diabetes type 2.

31. A method for generating a mutant insect, characterized in that adult animals are treated with a mutation generating means under mutation generating conditions, that thus treated insects are crossed to wild-type or mutant insects[, in particular *chico* mutant insects,] and that viable offsprings with altered cell number, cell size, developmental time [and/]or lipid levels are cultivated under suitable conditions.

32. The method of claim 31 wherein the adult animals are males.

33. The method of claim 31 wherein the treated insects are crossed with *chico* mutant insects.

34. The Mutant of claim 25 which is a Drosophila mutant.

IN VIVO INSECT MODEL SYSTEM FOR TYPE-2 DIABETES

Technical Field

The present invention concerns a tool for the investigation of diseases, in particular type-2 diabetes. The invention especially concerns an in vivo model that enables e.g. the screening of compounds suitable for therapy and diagnosis.

Background Art

Due to its homology with man, Drosophila might be a very useful in vivo model for the investigation of human diseases and for the drug screening, as long as the target to be investigated leads to an easily detectable change in the fly, such as size reduction.

Factors influencing the growth have already been extensively studied.

Much of the knowledge about growth regulation stems from studies done using tissue culture cell lines. A large number of peptide growth factors have been identified that stimulate cell division and survival of cultured cells. These observations have led to the hypothesis that regulation of overall growth is controlled primarily by coordinating cell cycle progression and cell survival (Raff, 1996). Although during development, the regulation of the cell cycle is tightly coupled to morphogenetic events (Edgar et al, 1994), several lines of evidence suggest that it may not be the primary determinant of growth regulation. Overall growth of an organ appears to be monitored by measuring total organ tissue volume and not be counting cell divisions. In mosaic wings consisting of haploid and diploid cells, haploid cells produce a normal sized compartment consisting of twice the number of cells (Santamaria, 1983). Moreover, if mitosis is blocked by

use of a temperature sensitive mutation in *cdc2* (Weigmann et al., 1997) or by overexpression of RBF, which is a negative regulator of the cell cycle (Neufeld et al., 1998), the result is normal sized compartments consisting of fewer but larger cells. Conversely, accelerating the cell cycle by overexpression of E2F, a positive cell cycle regulator produces more and smaller cells but does not alter clone size (Neufeld et al. 1998). Thus, changing the length of the cell cycle does not directly affect overall organ growth, which indicates that cellular growth can occur independently of cell cycle control.

In higher vertebrates, hormones and growth factors play an important role in the control of overall growth because they orchestrate cell growth, cell cycle, and cell survival. Reducing or increasing levels of growth hormone or of its mediators,IGF-1 and its receptor (IGFR), dramatically influence body and organ size (for review see Stewart and Rotwein, 1996). The control of cell survival can be an essential factor influencing overall growth (Raff, 1996).

Overall growth (and in some cases cell size) is also affected by the availability of nutrients. Many organisms have developed special survival strategies for periods of growth during low nutrition. Under inadequate nutritional conditions yeast cells, for example, reduce growth and divide at a smaller size (Thomas and Hall, 1997), whereas nematodes like *C. elegans* enter a diapause called the dauer stage (reviewed in Riddle, 1988; Cassada and Russel, 1975). When in this state, larvae arrest development in a sexually immature stage, alter their metabolism to increase the storage of fat, and live up to three times as long as under non-starved conditions (Cassada and Russel, 1975). Dauer formation in *C. elegans* is dependent on the cooperation of the insulin and TGF-β signalling pathways (Kimura et al., 1997). Raising Drosophila under adverse food conditions also results in

the production of small flies with fewer and smaller cells (Robertson, 1959; Bryant and Simpson, 1984). Still, little is known in higher organisms about how growth is controlled at the cellular level. In Drosophila, a class of mutations known as *Minutes (M)* dominantly delay development, and in some cases result in reduced body size. Some of the *M* genes encode ribosomal proteins and are thought to slow down growth by reducing protein synthesis (Lindsley and Zimm, 1992). Partial loss of function mutations in the Drosophila *myc* gene, diminutive, cause a reduction in overall body size (Gallant et al., 1996).

There has also already been described a P element induced Drosophila mutation, *fs(2)4*^{1}, as a female sterile, male fertile, mutation (Berg and Spradling, 1991). However, there is nothing disclosed about size differences or the place of the P-element induced mutation.

Thus, none of the documents of the state of the art suggests any applicability of such flies in the investigation of human diseases and/or for drug screening.

It is therefore still very much desired to get an in vivo model for such investigations.

Disclosure of the Invention

It has now surprisingly been found that the mutant strain, the phenotype of which was described by Berg and Spradling in 1991, after 7 years of storage lost its viability. The originally described female sterile phenotype could be restored by recombination. After recombination, two further phenotypes associated with the defect *fs(2)4*^{1} could be observed: Homozygous animals are reduced in size and adult fies have increased lipid levels. Furthermore it was discovered that the mutation

is located in the gene coding for the homolog of the insulin receptor substrate (IRS 1-4).

Due to the observed reduction in the body size, the gene affected by the P element and the mutant animal, in particular the mutant Drosophila, with a size reducing defect in said gene, are named *chico* which means small boy in Spanish.

The observed alterations in the body size and other characteristics of the mutant make such mutant animals very useful tools in the investigation of interactions with and mutations of the insulin signaling pathway.

Thus, one object of the present invention was to provide a method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, wherein a viable insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size and/or cell size and/or development time and/or lipid level is determined whereby alterations of the body size and/or cell size and/or development time and/or lipid level are detectable in at least part of the animal. Preferred animals for use in such method are animals with reduced *chico* function, e.g. with at least one nucleotide sequence being a *chico* mutation.

Another object of the present invention was to provide the *chico* gene and *chico* mutations, in particular size reducing *chico* mutations. *Chico* is of particular interest, since also homozygosity for *chico* causes only semi-lethality. Additionally, an overall delay in development has been observed. Homozygous *chico* animals eclose two or three days after their heterozygous siblings. Under noncrowded culture conditions, homozygous *chico* mutant females can produce few viable progeny lacking both maternal and zygotic *chico* function.

In the scope of the present invention, animal means insects, whereby preferred insects are flies and a preferred fly is Drosophila. Where in the scope of the further general description fly or Drosophila is mentioned, it has to be understood that - in not preferred embodiments of the present invention - also other animals of the above definition are encompassed in the respective disclosure.

The fact that insects with a mutation within the insulin signaling pathway show altered characteristics is e.g. shown in that mutant flies homozygous for *chico* are markedly reduced in size but survive. This shows that a total loss of *chico* activity is not lethal. Obviously, the insulin receptor (INR) pathway is thus that *chico* can - at least partially - be bypassed.

Due to this finding, *chico* mutant animals are not only suitable for drug screening, but also enable the search for possible further defects in the INR pathway or therewith interacting factors.

While for drug screening flies with two inactive *chico* mutants, one inactive *chico* mutant and one *chico* gene lost, or both *chico* genes lost are preferred, also flies with a reduced *chico* activity can be used as long as the mutant flies are sufficiently distinguishable from wild-type flies.

Such flies with reduced *chico* activity can either have two *chico* mutations with reduced activity both, one *chico* mutation with no and one *chico* mutation with reduced activity, or one *chico* totally lacking and one *chico* mutation with reduced activity.

Besides of drug screening, such *chico* mutant flies can also be used as sensitized model systems to find other key components in the INR pathway.

Although heterozygous *chico* flies with one functional *chico* are not easily distinguishable from wild-type flies, they are interesting models for finding

further key components in the INR pathway, whereby flies sensitized in *chico* and having a further non-lethal defect in another compound involved in the INR pathway, are again useful model systems for drug screening and search for further key components.

Flies comprising, besides *chico*, further mutations can be obtained by several methods known to the skilled person such as mutations induced by P element, chemical compounds, radiation etc. If a mutation of a known key component shall be introduced, this can furthermore be performed by destroying at least one respective wild-type gene and insertion of the desired mutation.

The preferred animal - as already mentioned above - is Drosophila due to the great knowledge on this fly, the high conservation of the genome and the fast reproduction. However, the high conservation makes also other insects suitable model systems, in particular other flies.

The applicability of *chico* mutations is not only particularly broad due to their specific characteristics, but also due to the fact that it is the first coupling element within the cell and thus situated at the very beginning of the cascade of components involved in the INR pathway.

The method of screening for compounds influencing the INR pathway involves *chico* mutant animals such that e.g. a single drug or a combination of two or more drugs is applied to the animal in as early development stage, e.g. to the larvae of said *chico* mutant flies and that at least one difference between treated and non treated animals in the juvenile or adult state, e.g. larvae or flies, respectively, is determined.

The time of the application is not critical. The application can be performed by injection, whereby a preferred method is injection into the egg, and a much preferred method is injection into the larvae. However,

for some applications, injection into the adult animal is also possible.

The determination of differences between treated and non-treated animals can be performed by measuring the weight, the cell size, the cell number or the lipid content per weight. The fact that *chico* affects not either cell size or cell number, but both is a very favorable characteristic if e.g. a second defect were present affecting either the number or the size only.

Thus, *chico* mutant flies, whether they have only *chico* mutations or furthermore another mutation in the INR pathway, are very useful tools for the screening of compounds improving the INR signalling pathway.

Brief Description of the Drawings

The invention will be better understood and objects other than those set forth above will become apparent when consideration is given to the following detailed description thereof. Such description makes reference to the annexed drawings, wherein:

Figure 1A shows the body size reduction of homozygous mutant animals at different development stages, whereby Drosophila with one wild-type *chico* (+) and one inactive *chico* allele (-) are marked as (+/-), Drosophila with two inactive *chico* alleles as (-/-) and control flies with two wild-type *chico* as (+/+), and whereby the $chico^{-/-}$ egg was derived from heterozygous *chico* females in which $chico^{-/-}$ germline clones had been generated. The $chico^{1}$ allele (P element insertion allele) was used for germ-line clones. In comparison, a heterozygous *chico* mutant egg ($chico^{+/-}$) is shown. Homozygous $chico^{-/-}$ larvae, pupae and adults were derived from heterozygous flies carrying the $chico^{2}$ allele.

Figure 1B shows the body weight of individual flies (n = 20) whereby the weights of *y w* control flies

(+/+), heterozygous (+/-) and homozygous mutant (-/-) *chico* flies are shown.

Figure 2 represents comparison of the cell size distribution of heterozygous (+/-) and homozygous mutant (-/-) *chico* wing disc cells determined by FACS analysis, whereby

Figure 2A represents dot blots of heterozygous (+/-) *chico* wing disc cells displaying forward scatter (FSC), which is a measurement for cell size, and side scatter (SSC), which is a measurement for cell granulation, and whereby

Figure 2B is an analogue representation as Figure 2A for homozygous (-/-) *chico* wing disc cells.

Figure 2C is a histogram that displays cell size (FSC) and cell number. Comparison of the mean value of the FSC in Figure 1A and Figure 1B of the gated cell population (R1) reveales that the mean value of the FSC of homozygous mutant *chico* cells is reduced by 10-14 percent in three independent experiments compared with the mean value of the FSC of heterozygous cells.

Figure 3A shows the genomic structure of the *chico* locus at 31B-C with the putative transcriptional start site lying 221 bp 3' from the end of *bsk* encoding DJNK. *ME31B* encodes a DEAD box RNA helicase (de Valoir et al., 1991). Comparison of the genomic and cDNA sequence revealed that the *chico* transcript contains 9 exons with the putative translational start site in the second exon. Black boxes represent translated exons and open boxes indicate untranslated exons. See text for details concerning the P element insertion, the deficiency chromosome, and the rescue constructs. H = HindIII; E = EcoR1.

Figure 3B shows the translated amino acid sequence wherein the black-boxed sequence represents the PH domain and the grey-boxed sequence the PTB domain, respectively, and wherein the putative DRK binding site

(YQN) and the two putative p60 PI3K binding sites (YIPM and YLEM) are highlighted.

Figure 3C shows a PH and PTB domain alignment, wherein the PH domain and the PTB domain of CHICO were aligned to human IRS-1,2,4 and mouse IRS-3, and wherein the dark boxes indicate amino acid identity, while the grey boxes indicate amino acid similarity. The lowercase letters in the consensus line represent identity in 3-4 of the proteins, while upper case letters represent identity in all proteins. The percentage identity was calculated by comparing CHICO individually to each mammalian IRS, and then averaging the four separate identities.

Figure 4A is a tangential section through an eye containing a CHICO (-/-) clone, whereby the *chico* (-/-) clone is recognized by the lack of pigment (bright ? passages). Within the clone, all photoreceptor (PR) cells are reduced in size by about 50 percent compared with wild-type PR cells (dark). At the border of the clone ommatidia composed of wild-type and small $chico^{-/-}$ mutant PR cells (arrow head) are visible, indicating that CHICO controls cell size autonomously. The numbers represent PR cells R1-R7.

Figure 4B is a comparison of wild-type flies with flies in which the *chico* function in the eye imaginal disc cells has been removed, thereby generating flies with a strongly reduced head capsule and reduced eyes, whereas the proboscis and the rest of the body are of wild-type size. The flies compared were of the following genotypes: (B, left panel) *y w ey-Flp; chico^{1} FRT40 / P(w^{+}) l(2)2L-3.1 FRT40; P(w^{+} chico genomic rescue construct pCSR4)/+*, (B, right panel) *y w ey-Flp; chico^{1} FRT40 / P(w^{+}) l(2)2L-3.1 FRT40* , (C, scanning electron micrograph, left panel) *y w ey-Flp; chico^{1} FRT40 / CyO,* (C, scanning electron micrograph, right panel) *y w ey-Flp; chico^{1} FRT40 / P(w^{+}) l(2)2L-3.1 FRT40.*

Figure 4C is an enlarged view of the head region of Figure 4B.

Figure 5A shows the fresh and dry weight of individual wild-type (+/+), heterozygous (+/-), and homozygous (-/-) *chico* mutant males, whereby measurement was made of individual adult males (n = 10) reared under the same growth conditions and analyzed three days after eclosion. The dry weight of wild-type, heterozygous and homozygous mutant males is approximately 28 percent of the corresponding fresh weight.

Figure 5B shows lipid, protein and glycogen contents of the same analytical group as in Figure 1A. As can be seen homozygous *chico* mutant (-/-) males contain almost twice as much lipid calories per milligram fresh weight compared with heterozygous (+/-) or wild-type (+/+) flies.

Modes for carrying out the invention

In order to use insects, in particular Drosophila mutants as in vivo monitoring system, the function of the defect gene and differences between wild-type Drosophila and *chico* mutant Drosophila have been studied.

Thereby it was found that *chico* encodes a homologue of vertebrate insulin receptor substrates, IRS1-4.

The insertion site of the P element in $chico^1$ was mapped 1.5 kb downstream of the *bsk* gene (Figure 3A). Isolation and analysis of partial cDNA clones, a full length EST clone and the corresponding genomic sequence flanking the P element insertion, indicated that the *chico* gene consists of a single transcription unit of 3.6 kb with 9 exons. The P element insertion is located 80 bp downstream of the putative translation initiation site in the PH domain (see below). The open reading frame codes for a protein product of 967 amino acids with a

calculated molecular weight of 97 kd. The CHICO amino acid sequence exhibits the strongest similarity with members of a family of vertebrate insulin receptor substrate proteins known as IRS1-4. Vertebrate IRS family members are characterized by an N-terminal pleckstrin homology (PH) domain, a phosphotyrosine binding (PTB) domain and by a number of phosphotyrosine motifs that can serve as docking sites for SH2-containing proteins (for review see Yenush and White, 1997).

The cDNA sequence (SEQ ID NOs 1, 2) of wild-type *chico* is shown in Table 1 together with the respective protein sequence, (SEQ ID NOs 2, 3) and the genomic DNA sequence (SEQ ID NO 4) is found in Table 2 below.

While the cDNA sequence shows the coding sequence only, the genomic sequence comprises functional flanking parts.

Furthermore, it has to be understood that all sequence related statements - also without specific mention - also concerns the complementary strand.

Table 1: cDNA and Protein Sequence

```
    154/1                                          184/11
    214/21                                         244/31

    ATG GCA TCA ATA TCG GAT GAC GGC ATG GCG CTG AGT GGC TAC CTC AAG AAG
    CTG AAG
    ACC ATG AAG AAG AAG TTC TTT GTG CTG TAC GAG GAG ACG AGC ACT TCG GCA
    GCC CGG
    CTG GAG
    Met ala ser ile ser asp asp gly met ala leu ser gly tyr leu lys lys
    leu lys
    thr met lys lys lys phe phe val leu tyr glu glu thr ser thr ser ala
    ala arg
    leu glu
    274/41                                         304/51
    334/61                                         364/71

    TAC TAC GAT ACC GAA AAG AAG TTC CTG CAA AGA GCC GAG CCA AAA AGG GTT
    ATA TAT
    CTG AAG AAT TGC TTC AAC ATC AAT CGC CGT TTG GAC ACC AAG CAT AGA TTT
    GTC ATT
    GTG CTC
    tyr tyr asp thr glu lys lys phe leu gln arg ala glu pro lys arg val
    ile tyr
    leu lys asn cys phe asn ile asn arg arg leu asp thr lys his arg phe
    val ile
    val leu
    394/81                                         424/91
    454/101                                        484/111

    TCC TCC AGA GAC GGT GGA TTC GGC ATC GTT CTC GAG AAC GAA AAT GAT TTA
    CGC AAA
    TGG TTG GAC AAA CTA CTA GTT CTA CAA AGG AAC ATA GCC AAT TCG AAT GGA
    ACA GCG
    CAC TCA
    ser ser arg asp gly gly phe gly ile val leu glu asn glu asn asp leu
    arg lys
    trp leu asp lys leu leu val leu gln arg asn ile ala asn ser asn gly
    thr ala
    his ser
    514/121                                        544/131
    574/141                                        604/151

    CCT TAT GAC CAC GTT TGG CAA GTT GTC ATT CAA AAG AAG GGT ATT TCG GAG
    AAA GTT
    GGA ATC ACC GGA ACC TAC CAC TGT TGC CTT ACT TCA AAA TCC CTG ACA TTC
    GTG TGC
    ATT GGA
    pro tyr asp his val trp gln val val ile gln lys lys gly ile ser glu
    lys val
    gly ile thr gly thr tyr his cys cys leu thr ser lys ser leu thr phe
    val cys
    ile gly
    634/161                                        664/171
    694/181                                        724/191
```

CCG GAG AAG ACG CCC AAT GGC GAG GAT CGC GTT GCG AGC ATT GAA ATA CTT
TTG ACC
ACG ATC AGG CGA TGC GGT CAT GCA TCC CCA CAA TGT ATA TTC TAC GTG GAA
CTT GGC
CGC CAA
pro glu lys thr pro asn gly glu asp arg val ala ser ile glu ile leu
leu thr
thr ile arg arg cys gly his ala ser pro gln cys ile phe tyr val glu
leu gly
arg gln
754/201 784/211
814/221 844/231

AGT GTC TTG GGA TCT GGT GAT CTG TGG ATG GAG ACG GAT AAC GCA GCT ATT
GCT ACT
AAT ATG CAC AAC ACG ATA CTG AGC GCT ATG TCA GCC AAA ACA GAG TCG AAC
ACG AAT
TTA ATA
ser val leu gly ser gly asp leu trp met glu thr asp asn ala ala ile
ala thr
asn met his asn thr ile leu ser ala met ser ala lys thr glu ser asn
thr asn
leu ile
874/241 904/251
934/261 964/271

AAC GTT TAT CAG AAT AGA CCT GAC TTA AGT CAC GAG CCC ATG AGA AAG CGA
TCG TCG
TCT GCA AAC GAA GCA TCG AAG CCG ATA AAC GTA AAT GTC ATA CAA AAT AGT
CAA AAC
TCT CTC
asn val tyr gln asn arg pro asp leu ser his glu pro met arg lys arg
ser ser
ser ala asn glu ala ser lys pro ile asn val asn val ile gln asn ser
gln asn
ser leu
994/281 1024/291
1054/301 1084/311

GAA TTG CGC AGC TGC AGT TCG CCC CAT AAC TAT GGT TTC GGC AGA GAG AGA
TGC GAT
AGC TTA CCA ACC AGA AAT GGA ACC CTA AGC GAG TCC AGC AAT CAA ACG TAC
TTT GGT
TCC AAC
glu leu arg ser cys ser ser pro his asn tyr gly phe gly arg glu arg
cys asp
ser leu pro thr arg asn gly thr leu ser glu ser ser asn gln thr tyr
phe gly
ser asn
1114/321 1144/331
1174/341 1204/351

CAT GGA CTG CGA TCC AAT ACT ATA TCT GGC ATC CGT CCG CAC TCA ACC AAC
AAG CAT
AGT AAT AGT CCA ACG TTC ACC ATG CCA TTA AGA TGC TCA GAA TCC GAA GAG
TCA TCA
ATT AGT
his gly leu arg ser asn thr ile ser gly ile arg pro his ser thr asn
lys his

ser asn ser pro thr phe thr met pro leu arg cys ser glu ser glu glu
ser ser
ile ser
1234/361 1264/371
1294/381 1324/391

GTC GAT GAA TCC GAC GAC AAC GGC AGT TTT AGC CAC TAC AGA TTA AAC ACG
CGG TCA
TCT GAG ACG GCA ATT CCT GAG GAA AAC ATT GAT GAC TTT GCC AGT GCG GAA
TTA TTT
AGC AAA
val asp glu ser asp asp asn gly ser phe ser his tyr arg leu asn thr
arg ser
ser glu thr ala ile pro glu glu asn ile asp asp phe ala ser ala glu
leu phe
ser lys
1354/401 1384/411
1414/421 1444/431

GTC ACC GAA CAA AAT GTA AGT GAC GAA AAC TAC ATA CCG ATG AAT CCA GTC
AAT CCT
ACC GAT GCT ATC CAT GAA AAG GAG AAG GCT GAT ATG CAG AGA TTG GAA GAT
GCT TCG
CTG CAT
val thr glu gln asn val ser asp glu asn tyr ile pro met asn pro val
asn pro
thr asp ala ile his glu lys glu lys ala asp met gln arg leu glu asp
ala ser
leu his
1474/441 1504/451
1534/461 1564/471

TTC AAC TTT CCG GAG CAC GCG TCG GAA AAG CTT GCT AAG GAT TTT GAT CTG
GAC TCT
GAT AAC CAA TGC TGT CGT CCC ATT CGC GCC TAT TCG ATA GGC AAC AAG GTT
GAG CAT
TTA AAG
phe asn phe pro glu his ala ser glu lys leu ala lys asp phe asp leu
asp ser
asp asn gln cys cys arg pro ile arg ala tyr ser ile gly asn lys val
glu his
leu lys
1594/481 1624/491
1654/501 1684/511

TTT AAT AAG CGC CTG GGA CAC TTG AAT GAT ACG GGA CAG AAT CCG AAT CGC
GTG CGA
GCC TAC TCG GTT GGC TCC AAA TCG AAG ATA CCG CGC TGC GAC CTG CAG CGA
GTG GTC
CTC GTG
phe asn lys arg leu gly his leu asn asp thr gly gln asn pro asn arg
val arg
ala tyr ser val gly ser lys ser lys ile pro arg cys asp leu gln arg
val val
leu val
1714/521 1744/531
1774/541 1804/551

GAG GAC AAT AAA CAT GAG TTC ACA GCG AAT AGG AGT CAG AGT AGC ATT ACC
AAG GAA

GGA ACC AGC TAT GGC AGC AGT GCC AAT CGA CAA AAG AAG TCC ACA AGT GCT
CCA CTC
CTC AGT
glu asp asn lys his glu phe thr ala asn arg ser gln ser ser ile thr
lys glu
gly thr ser tyr gly ser ser ala asn arg gln lys lys ser thr ser ala
pro leu
leu ser
1834/561 1864/571
1894/581 1924/591

CTG AAG AAC CAG ATA AAC TCC GAC CGA ATG AGT GAC TTA ATG GAA ATT GAT
TTT TCA
CAA GCA ACC AAT TTG GAA AAG CAG AAG TTC ATC AAG AAT AAT GAA ATT CCG
AAA TAC
ATT GAA
leu lys asn gln ile asn ser asp arg met ser asp leu met glu ile asp
phe ser
gln ala thr asn leu glu lys gln lys phe ile lys asn asn glu ile pro
lys tyr
ile glu
1954/601 1984/611
2014/621 2044/631

AAC GTG TTC CCA AAA GCC CCG CGA ACG GAT AGC TCC AGC CTA ACT CTG CAC
GCC ACA
AGT CAA AAG GAC ATT TTC AAT GGC ACC AAA CTA AAT AAC ACT GCG ATC ACA
TCC GAG
GAT GGT
asn val phe pro lys ala pro arg thr asp ser ser ser leu thr leu his
ala thr
ser gln lys asp ile phe asn gly thr lys leu asn asn thr ala ile thr
ser glu
asp gly
2074/641 2104/651
2134/661 2164/671

TAC CTC GAG ATG AAG CCA GTC GGT AAT GGA TAC ACT CCC AGT TCG AAT TGC
CTG CCA
ATG AAA GTG GAG AAA CTC AAG CTA TCC GAC TAT CAG ACA GCA CCG CCA CTC
ACC GCA
ACA GCC
tyr leu glu met lys pro val gly asn gly tyr thr pro ser ser asn cys
leu pro
met lys val glu lys leu lys leu ser asp tyr gln thr ala pro pro leu
thr ala
thr ala
2194/681 2224/691
2254/701 2284/711

GCA CCA GTG CAC GAT TTA AAC AAA ATT AGC ACA TAC AAT ATA TCC GCT GAG
AAA TGG
AGA GAA CAG CCC AGC AGA AGC GAG GAA AAG AAG TCG AAC TCG CCA TTG AAT
GAC AAC
ACC TTT
ala pro val his asp leu asn lys ile ser thr tyr asn ile ser ala glu
lys trp
arg glu gln pro ser arg ser glu glu lys lys ser asn ser pro leu asn
asp asn
thr phe

2314/721 2344/731
2374/741 2404/751

AGC TCG AAA CCC ACA AAT GTC GAG AGT ACA AGC AAA AGC CAT GAT GTT CAT
TCA GCA
AAT CAA ATT GAT TGC GAG AAA GTG TGC GCG CAG AGC AGC GAT AAG CTA AAT
AAT CAT
CTG GCC
ser ser lys pro thr asn val glu ser thr ser lys ser his asp val his
ser ala
asn gln ile asp cys glu lys val cys ala gln ser ser asp lys leu asn
asn his
leu ala
2434/761 2464/771
2494/781 2524/791

GAC AAG ATT GTC GAG AAC AAC AAT TTG GAT ATA GGC GGG CAT GAG GAA AAG
AAG TTG
GTT CAT TCG ATA AGC AGC GAA GAC TAC ACA CAA ATC AAG GAC AAA TCG AAT
GAT TTC
ACA AAA
asp lys ile val glu asn asn asn leu asp ile gly gly his glu glu lys
lys leu
val his ser ile ser ser glu asp tyr thr gln ile lys asp lys ser asn
asp phe
thr lys
2554/801 2584/811
2614/821 2644/831

TTT AAC GAA GCC GGC TAC AAA ATT CTG CAA ATT AAA AGC GAC AGC TCA CTC
ATC TCA
TCG AAG CTA TAC CAA AAG GGT ATA CAC AAG GAT AAC TTG GAG CGT TCG CAG
AGA CTT
ACA GAG
phe asn glu ala gly tyr lys ile leu gln ile lys ser asp ser ser leu
ile ser
ser lys leu tyr gln lys gly ile his lys asp asn leu glu arg ser gln
arg leu
thr glu
2674/841 2704/851
2734/861 2764/871

AGT GTG AAT ACG ATT CCC GAT AAT GCC ACC GCC ACC GCG GTG AGC AGC AGC
TCA CTC
ACC AAA TTC AAT ATA AAT TCA GCA AAG CCA GCC GCC GCC GCC GAT TCG CGT
AGC ACT
GGC ACA
ser val asn thr ile pro asp asn ala thr ala thr ala val ser ser ser
ser leu
thr lys phe asn ile asn ser ala lys pro ala ala ala ala asp ser arg
ser thr
gly thr
2794/881 2824/891
2854/901 2884/911

GAT CCA AGT ACA CCA CAG AAC ATT CTA CAG ATT AAA GAT TTG AAT TTC CCC
TCA AGG
TCG TCG TCT CGC ATA TCC CAG CCG GAG CTG CAC TAC GCC AGC CTA GAT CTT
CCC CAT
TGC AGT

asp pro ser thr pro gln asn ile leu gln ile lys asp leu asn phe pro
ser arg
ser ser ser arg ile ser gln pro glu leu his tyr ala ser leu asp leu
pro his
cys ser
2914/921 2944/931
2974/941 3004/951

GGC CAA AAT CCA GCT AAA TAC CTG AAG AGA GGA TCA CGC GAA TCG CCG CCG
GTG TCC
GCA TGC CCG GAG GAT GGG AAT ACC TAT GCG AAA ATC GAC TTT GAC CAA TCC
GAC TCC
TCT TCC
gly gln asn pro ala lys tyr leu lys arg gly ser arg glu ser pro pro
val ser
ala cys pro glu asp gly asn thr tyr ala lys ile asp phe asp gln ser
asp ser
ser ser
3034/961
TCC TCA TCG AAC ATA TTT AAT ACG TAA
ser ser ser asn ile phe asn thr OCH

Table 2: Genomic DNA sequence

AGAACGACTTTTTCCTCCTTAGTCAGTCACAAGAAAACTAAAGCTTACCA
ACAATACGGCGTGTATTGTTAAATTATTACAACAAATAAAATATTCAAAT
TGTATTTAAAAATATAGTAACCATTAAAAAATAAAATCAATATGCGAAAC
TTTGTAATTTCTTACTCATCCTTGTTTTTTGAGCCCGCTTTCTTAAGTTA
AATCGTTAAAATACCAGTTTAATCATTTCATTGTCCTGATTTCAGGAGCT
AATTACATTTTAATCTTTGTATAAATTCATAAAATTAAAATGGAAATGTT
TAACCACATAAAATATTTGGGTATATAAAGTCGATACATACTTTTAAAAT
TTTGTTTCATACAAGAATATGGAAAGTAGATAATTTAGTTACCGATTAAA
ACATTTCTAAAATACAAAAAATTTAAAATGATGATTAAATAAAAAACTGT
TATACTAAATTTAAACGAAACAAACGGTCATTCGATAACTCAATTAGTAT
CGAATAAGCCGGCGTGTAAATCGGGTTGGCAACTCTCACCGGTGTAGAGA
TCGGGATGGCAACTTCGTATTGTTATTCCTATGCTGCGATAACGATAACA
GCAAAGTGTCATCGCGAATAAATGTGGGTTTGATAATAAAGAATTGCGTT
GGTGAACAATAATAATACAAATGCTAAATGTATCGCGCGGATAACTAGTA
AACACTGATTTCGCGCATATCGGGCATACGGGCAGCTAGACGTCTTAGGT
AACACATTTCCCAGCCACATTGGCGTTGAGGTATTATTTCCCATATCCAT
GTGCGTTTGTAAATGATACCACCAGAGTGTGCCATATGTATCGTTGTTTG
TACATACATGCCTACGGGGAAAAATAACTCGCAGATACATATGTATGTAA
GATGTATTAGAATTCCACAGATATATGTACATATAAATATATATATATAT
TTATGATGCTCATCTATAAAACAAAATATGTACAAACATACGCGCGCACG
TACTTATGTATGTACATATACATATATACATATATGTATAATAAAATGAG
CATCTAGCTGCGGTTATCTTAATGCAATGCGCAGAAACCTGAAAACGAAA
TAAACAATCTTTACAGCGCCAGCACAGTGAGCCAATTATGAATTCACAAT
TCCACATCCAATTCCGATTCCGAATTCCATCGCTTTACATCCTAATTCGA
ATACGTCGCGCCGCGTAAGCTGCACTCGAATATTGACATAAACGACGTAA
TTGCGTGTTTTGATTGCGATTTCCGATGCTCGATGTTGACAGACGGCAAG
GATTTTTTTTGCCAGCCGACATTGCGAATGCTTTTCGCGTGTTTGCGTTG
TGAAAAGCGATTTGTTGTTCCGGCAGTTGGAAATGTTTTGTGCTGTTTAT
GCTTAGAAAAGCAAATGTATTGCACAAAACTCGTGTTTCCTACATTAGTA
AAGCCTATAACTTAGGTATATGTTTCTAAATTACAATGCAAAAAATAAAA
AACATTATACATGTGTTCGTTCTTTAATTTGAAAACAGAAAAGTGAAAGC
CTTGCAAATCAAATATGTGTCCATATCGCCTACTAATAATATAAACACGT
CGCCTTCCAGGAACTAAGATTGGAAATCATGGCATCAATATCGGATGACG
GCATGGCGCTGAGTGGCTACCTCAAGAAGCTGAAGACCATGAAGAAGAAG
TTCTTTGTGCTGTACGAGGAGACGAGCACTTCGGCAGCCCGGCTGGAGTA
CTACGATACCGAAAAGAAGTTCCTGCAAAGAGCCGAGCCAAAAAGGGTTA
TCTATCTGAAGAATTGCTTCAACATCAATCGCCGTTTGGACACCAAGCAT
AGATTTGTCATTGTGCTCTCCTCCAGAGACGGTGGATTCGGCATCGTTCT
CGAGAACGAAAATGATTTACGCAAATGGTTGGACAAACTACTAGTTCTAC
AAAGGAACATAGCCAATTCGAATGGAACAGCGCACTCACCTTATGGTATG
CCAAATAAACTATAACTACCAGTTAGTATGAAACCTAAACACTTCATTTC
ACTTTGCAGACCACGTTTGGCAAGTTGTCATTCAAAAGAAGGGTATTTCG
GAGAAAGTTGGAATCACCGGAACCTACCACTGTTGCCTTACTTCAAAATC
CCTGACATTCGTGTGCATTGGACCGGAGAAGACGCCCAATGGCGAGGATC
GCGTTGCGAGCATTGAAATACTTTTGACCACGATCAGGCGGTTAGTTGTT
GCCAGCAAAACTGCAAGGGATTGTAAAATAATTCGGACTTAATTTCAGAT
GCGGTCATGCATCCCCACAATGTATATTCTACGTGGAACTTGGCCGCCAA
AGTGTCTTGGGATCTGGTGATCTGTGGATGGAGACGGATAACGCAGCTAT
TGCTACTAATATGCACAACACGATACTGAGGTATTTAGCTCTCATTACAA
CTAATCCAAGATTTCATGATCATCCTACAAAACGACATAGATAGTTTAAG
ATATCTCCCAGTTAACTTTAATAATTCTGTGGGTTTTTTCTTTCAGCGCT
ATGTCAGCCAAAACAGAGTCGAACACGAATTTAATAAACGTTTATCAGAA
CAGACCTGACTTAAGTCACGAGCCCATGAGAAAGCGATCGTCGTCTGCAA
ACGAAGCATCGAAGCCGATAAACGTAAATGTCATACAAAATAGTCAAAAC

TCTCTCGAATTGCGCAGCTGCAGTTCGCCCCATAACTATGGTAAATACTT
CAAATGTATGTTTAAACGCAAAATTAATCAAACGCAATCGTTTCAGGTTT
CGGCAGAGAGAGATGCGATAGCTTACCAACCAGAAATGGAACCCTAAGCG
AGTCCAGCAATCAAACGTACTTTGGTTCCAACCATGGACTGCGATCCAAT
ACTATATCTGGCATCCGTCCGCACTCAACCAACAAGCATAGTAATAGTCC
AACGTTCACCATGCCATTAAGATGCTCAGAATCCGAAGAGTCATCAATTA
GTGTCGATGAATCCGACGACAACGGCAGTTTTAGCCACTACAGATTAAAG
TGCGTTGCTATCAAATAATAATTATTTAATAATAATCACCATTTCAATTT
CTAGCACGCGGTCATCTGAGACGGCAATTCCTGAGGAAAACATTGATGAC
TTTGCCAGTGCGGAATTATTTAGCAAAGTCACCGAACAAAATGGTAAGCC
AAACACAAAAACAATTTTTTAACATGAAAAGTAGCTAATCAATTGGCTTT
GTTTAACTGCAGTAAGTGACGAAAACTACATACCGATGAATCCAGTCAAT
CCTACCGATGCTATCCATGAAAAGGAGAAGGCTGATATGCAGAGATTGGA
AGATGCTTCGCTGCATTTCAACTTTCCGGAGCACGCGTCGGAAAAGCTTG
CTAAGGATTTTGATCTGGACTCTGATAACCAGTGAGTACACATTTCGCTT
CAACTGTGCCACGTAATGCAATCAATCACATCTTGTTACAGATGCTGTCG
TCCCATTCGCGCCTATTCGATAGGCAACAAGGTTGAGCATTTAAAGTTTA
ATAAGCGCCTGGGACACTTGAATGATACGGGACAGAATCCGAATCGCGTG
CGAGCCTACTCGGTTGGCTCCAAATCGAAGATACCGCGCTGCGACCTGCA
GCGAGTGGTCCTCGTGGAGGACAATAAACATGAGTTCACAGCGAATAGGA
GTCAGAGTAGCATTACCAAGGAAGGAACCAGCTATGGCAGCAGTGCCAAT
CGACAAAAGAAGTCCACAAGTGCTCCACTCCTCAGTCTGAAGAACCAGAT
AAACTCCGACCGAATGAGTGACTTAATGGAAATTGATTTTTCACAAGCAA
CCAATTTGGAAAAGCAGAAGTTCATCAAGAATAATGAAATTCCGAAATAC
ATTGAAAACGTGTTCCCAAAAGCCCCGCGAACGGATAGCTCCAGCCTAAC
TCTGCACGCCACAAGTCAAAAGGACATTTTCAATGGCACCAAACTAAATA
ACACTGCGATCACATCCGAGGATGGTTACCTCGAGATGAAGCCAGTCGGT
AATGGATACACTCCCAGTTCGAATTGCCTGCCAATGAAAGTGGAGAGGCT
CAAGCTATCCGACTATCAGACAGCACCGCCAATCACCGCAACAGCCGCAC
CAGTGCACGATTTAAACAAAATTAGCACATACAATATATCCGCTGAGAAA
TGGAGAGAACAGCCCAGCAGAAGCGAGGAAAAGAAGTCGAACTCGCCATT
GAATGACAACACCTTTGGCTTGAAACCCACAAATGTCGAGAGTACAAGCA
AAAGCCATGATGTTCATTCAGCAAATCAAATTGATTCCGAGAAAGTGTGC
GCGCAGAGCAGCGATAAGCTAAATAATCTGGCCGACAAGATTGTCGAGAA
CAACAATTTGGATATAGGCGGGCATGAGGAAAAGAAGTTGGTTCATTCGA
TAAGCAGCGAAGACTACACACAAATCAAGGACAAATCGAATGATTTCACA
AAATTTAACGAAGCCGGCTACAAAATTCTGCAAATTAAAAGCGACAGCTC
ACTCATCTCATCGAAGCTATACCAAAAGGGTATACACAAGGATAACTTGG
AGCGTTCGCAGAGACTTACGGAGAGTGTGAATACGATTCCCGATAATGCC
ACCGCCACCGCGGTGAGCAGCAGCTCACTCACCAAATTCAATATAAATTC
AGCAAAGCCAGCCGCCGCCGCCGATTCGCGTAGCACTGGCACAGATCCAA
GTACACCACAGAACATTCTACAGATTAAAGATTTGAATTTCCCCTCAAGG
TCGTCGTCTCGCATATCCCAGCCGGAGCTGCACTACGCCAGCCTAGATCT
TCCCCATTGCAGTGGCCAAAATCCAGCTAAATACCTGAAGAGAGGATCAC
GCGAATCGCCGCCGGTGTCCGCATGCCCGGAGGATGGGAATACCTATGCG
AAAATCGACTTTGACCAATCCGACTCCTCTTCCTCCTCATCGAACATATT
TAATACGTAAAGTTTTGAAATTTATGACCCTATCCTATATATATGATTTG
TTTAATATTGTACATTTATTGTAAATATTCTCTGACAAGCAAAGCTTACA
ATTTTGGATGCTAATAAATAAATTTTATTTAAATTATAATGATCCCTTTG
GACTTTTTTTTTTTTTGGACTAAGAAATCACTACTAAAGAAGGGCTTTTC
GAGGGTTAAA

Sequence similarity between CHICO and IRS1-4 is confined to the N-terminal region including the PH domain and the PTB domain. The amino acid identity is 41 percent in the PH domain and 38 percent in the PTB domain (Figure 3B and C). Although there is no significant overall homology within the C-terminal domain, the CHICO protein contains several putative SH2 binding motifs characteristic for IRS family members. Two motifs at positions 411 and 641 fit the consensus binding site (YXXM) for the p85/p60 adaptor subunit of P110 PI(3)K (Songyang et al., 1993; Weinkove et al., 1997) and one (at position 243) corresponds to the consensus (YXN) for GRB2/DRK binding (Olivier et al., 1993; Songyang et al., 1993).

Owing to the insertion of the P element 80 bp downstream of the translation start site *chico*^{1} is likely to be a null mutation. The *chico*^{2} allele is a synthetic deletion allele covering the putative translation start site and the regulatory region of *chico* (Figure 3A; see experimental procedures). Flies homozygous for this synthetic *chico* null allele were viable and showed phenotypes indistinguishable from flies homozygous for *chico*^{1} (Figure 1B). The mutant phenotype of both alleles is fully rescued by an 8 kb genomic rescue construct encompassing the *chico* transcription unit and its endogenous regulatory sequences (Figure 3A). Therefore the reduction in body size and the female sterility is caused by the loss of *chico* function.

In order to profit from the close similarity of *chico* with IRS 1-4, clearly detectable, and preferably quantifiably differences between *chico* mutants and wild-type flies must exist.

Therefore, specific differences have been searched for and studied.

To quantify size differences in various mutants, the weight of individual flies was determined (Figure 1B). Flies homozygous for the P element (*chico*^{1})

or a synthetic *chico* deletion (*chico*^{2}) have a drastic weight reduction (by 65% in females and 55% in males) compared with wild-type control flies of the same age. Body size reduction is observed at all developmental stages, but does not alter the overall proportions of the flies (Figure 1A).

Since the reduction in body and organ size in *chico* mutants could be due to a reduction in the number of cells and/or a reduction in the size of the individual cells, cell number and cell size in the wing was determined. In the wing, each epithelial cell secretes cuticle with a single hair, so that counting the number of hairs and determining their density provides a direct measure of cell number and cell size in the wing. (See Table 3)

Table 3: Cell Size and Cell Number are Affected in Wings of Homozygous Mutan Animals[a]

Genotype	1 Area[b,c] ($10^6\mu m^2$)	2 Overall size reduction (%)	3 Cell density[d] (cells/μm^2)	4 Area covered per cell[e] (μm^2)	5 Cell size reduction (%)	6 Approx. No. of cells in measured area[b,f]	7 Cell number reduction (%)
y,w; +/Sp	1.47±0.009	-----	$6.38x10^{-3}\pm0.1x10^{-3}$	157±2.36	-----	9379	-----
y,w;*chico*^{2}/Sp	1.40±0.018	4.8	$6.32x10^{-3}\pm0.1x10^{-3}$	158±2.90	0	8848	5.7
y,w;*chico*^{2}/*chico*^{2}	0.89±0.009	39.5	$7.70x10^{-3}\pm0.1x10^{-3}$	130±1.66	17.2	6853	27

[a] From females at least eight wings of each genotype were analyzed.

[b] The area of the whole wing was integrated exclusive the alula and the costal cell.

[c] Measured using NIH Image 1.60.

[d] Assessed by counting number of wing hairs on the dorsal wing surface in a 10 000 μm^2 area just posterior to the PCV.

[e] Reciprocal of column 3.

[f] Generated by multiplying the values in column 1 by those in column 3.

As shown in Table 3, the 40 percent reduction in the size of *chico* mutant wings is caused by a reduction in both cell number and cell size. Reduction in cell number accounts for 68 percent of the total reduction in wing size. The remaining 32 percent of the reduction in wing size is due to a reduction in the average size of mutant cells. Similar results were obtained for the eye. It could be shown that in homozygous mutant *chico* flies, ommatidial number is reduced by approximately 40 percent: homozygous *chico* flies have only about 480 ommatidia per eye (Table 4) whereas wild-type flies have approximately 780 ommatidia per eye. Therefore, loss of *chico* function reduces body size by means of reducing cell number and cell size.

To test whether the reduction in the size of *chico* mutant cells is also observed during larval stages third instar wing discs of larvae homozygous or heterozygous for *chico* were dissociated and the relative cell size of the two cell populations was determined by FACS analysis (Figures 2A to 2C). A 10-14 percent reduction in the mean of the forward scatter of homozygous *chico* cells compared with heterozygous cells indicates that the size of *chico* imaginal disc cells is also reduced.

Since the effect of loss of *chico* function on the overall body and organ size could be due to a non-autonomous role of *chico* in humoral growth regulation or to an autonomous role in a tissue and cell type specific manner, the autonomy of *chico* was investigated. To test the cell autonomy of the *chico* mutation, clones of genetically marked homozygous mutant *chico* cells in a heterozygous background in the eye were generated (Figure 4A) using the hs-FLP/FRT system (Xu and Rubin, 1993). In each ommatidium, the R1-R6 photoreceptor cells are arranged in an asymmetric trapezoid. The tall side of the trapezoid is formed by photoreceptors R1-R3 facing

anteriorly. The centrally located R7 photoreceptor has a smaller rhabdomere than the six outer cells. Each of these morphological characteristics is retained in *chico* mutant ommatidia. Thus, loss of *chico* function does not impair the specification of cell fate. However, it is striking that the size of each mutant photoreceptor and hence the entire ommatidial unit in the mutant clone, is reduced by more than 50 percent. On the periphery of the clones of homozygous mutant tissue, ommatidia consist of homozygous and heterozygous cells. The genotype of each photoreceptor can be assessed by the presence or absence of red pigment. Small homozygous mutant photoreceptor cells (arrowheads in Figure 4A) coexist with heterozygous cells in the same ommatidium. Remarkably, this does not significantly alter the shape of the ommatidia and the arrangement of the photoreceptors. Autonomy of cell size control is also observed in the wing (data not shown). Therefore, final cell size is autonomously dependent on *chico* function in each individual cell.

In order to further study the effects of *chico*, it was tested whether *chico* affects the size of organs and body parts autonomously. For this testing, *chico* function was selectively removed in the eye imaginal disc using the *eye-FLP* technique (see Example 4). The results presented here, show that selected removal of *chico* function in the head using the eye-FLP technique reduces head size. This reduced head size phenotype can be used to identify mutations in other genes that affect growth and thus are likely to encode components of the insulin signalling pathway. These mutations thus identify genes that are potential drug targets for human diseases such as type-2 diabetes. The eye imaginal disc gives rise to the compound eye and the head capsule but not to the proboscis. In embryos heterozygous for *chico*, mitotic recombination was selectively induced in the eye progenitor cells by using an FLP recombinase driven by the eyeless-enhancer

(Quiring et al., 1994). Owing to the presence of a recessive mutation affecting cell survival on the *chico*$^{+}$ chromosome, *chico* homozygous mutant cells have a proliferative advantage and contribute to the majority of cells in the eye and the head. Thus flies have heads that are largely homozygous for *chico* while the rest of the body is heterozygous. In such flies, the eyes and the head capsule are strongly reduced in size while the proboscis and the rest of the body are of wild-type size (Figure 4B, C). Thus *chico* acts autonomously in the control of cell size and organ size.

It was furthermore investigated whether the reduction in cell number caused by the absence of *chico* function is the result of a prolonged cell cycle time or of an increased rate of apoptosis during development. In order to analyze the behavior of *chico* mutant cells during development, genetically marked homozygous mutant cells were generated by mitotic recombination. This allowed comparision between the behavior of homozygous mutant clones and their wild-type sister clones, called twin spots, generated during mitotic recombination. Three differences between mutant and wild-type twin clones are obvious: first, *chico* mutant clones are rare: in approximately 90 percent of the clones, only the darkly pigmented wild-type twin spot can be detected. This is most likely due to the fact that small mutant clones encompass only a few ommatidia and escape detection. Secondly, when a non-pigmented mutant clone is detected, the clone is variable in size and often significantly smaller than the wild-type sister clone. Thirdly, there are regional differences in the frequency of mutant clones: clones are more frequently observed in the anterior half of the eye around the equator. The equator defines a line of dorso-ventral mirror image symmetry in the orientation of the ommatidial units. It appears that mutant cells have a better chance to grow or survive in the center of the eye than on its periphery. The behavior

of *chico* mutant clones is similar to that of *M* mutant clones and has been described as cell competition (Morata and Ripoll, 1975; Simpson, 1979). It indicates that the development of *chico* mutant cells is selectively impaired compared with wild-type cells and that there are regional differences in the ability of mutant cells to grow or survive.

In addition, mutant clones in the eye and wing imaginal discs were tested to investigate whether the reduced size of *chico* mutant clones observed in the adult is due to a growth disadvantage or to impaired cell survival during the final stages of differentiation. This investigation was performed on eye imaginal discs containing *chico* mutant or wild-type control clones, marked by the absence of the green *arm-lacZ* staining, and their intensely bright green staining twin spots. As seen in the adult, the mutant clones are smaller than their twin spots and are variable in size. The clones often form a thin line. The fact that *chico* mutant clones in the third instar disc and in the adult eye exhibit a similar behavior argues against the possibility that homozygous mutant *chico* cells are eliminated during differentiation in the pupal stage.

As a critical determinant of organ size through counterbalancing cell proliferation, apoptosis has been postulated (Conlon and Raff, 1999). In order to test whether programmed cell death contributes to size control by reducing cell number, discs containing either *chico* mutant clones or wild-type control clones were analyzed by terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labelling (TUNEL). No significant difference in occurence of apoptotic cells between wild-type and mutant clones was detected (data not shown). Since *chico* mutant clones are rather small, mutant clones in a *Minute* background were induced. Even though such clones were greatly enlarged due to their growth advantage they also did not reveal enhanced

apoptosis compared with wild-type control clones in a *Minute* background (data not shown). Furthermore, no increase in morphological signs of programmed cell death such as enlarged cells or cells with picnotic nuclei in *chico* mutant clones was observed, neither in the imaginal discs nor in the adult eye. These results are also consistent with the FACS analysis of heterozygous and homozygous *chico* mutant wing disc cells. No significant difference in the apoptotic sub-G1 fraction of homozygous *chico* mutant cells compared with heterozygous cells was detected (data not shown). Therefore, these results show that *chico* function is not necessary for cell survival, but is required for cell growth and cell proliferation throughout development. Homozygous *chico* mutant cells have a selective growth disadvantage: they grow more slowly than wild-type cells, as indicated by their under-representation in discs and in the adult eye, and they cannot reach the normal size of wild-type cells. The cell cycle profiles of heterozygous and homozygous *chico* mutant wing disc cells, however, are similar (data not shown) suggesting that the increased cell cycle time of *chico* mutant cells is caused by proportional expansion of the G1, S and G2 phase of the cell cycle.

It was also found that *chico* interacts with other essential compounds. Such compounds with which *chico* genetically interacts are the Drosophila insulin receptor and *PI(3)kinase*. Due to the found homology of CHICO with mammalian IRS1-4, genetic interactions with other components involved in signaling via IRS proteins, such as the insulin receptor and the p110 PI3kinase (PI3K), can be studied. Loss of function mutations in *Inr* are lethal but certain heteroallelic combinations survive to adulthood. Such *Inr* mutant flies are reduced in size (Chen et al., 1996). It was found that, like in *chico* mutants, cell size is reduced by 28 percent in Inr^{313}/Inr^{327} flies. Furthermore targeted expression of a dominant negative variant of Drosophila p110 PI3K in the

developing eye or wing causes a reduction in cell size in the eye, and in both cell size and cell number in the wing. Conversely, overexpression of a constitutively active, membrane-targetted version of PI3K increases cell size and cell number (Leevers et al., 1996). In flies that are homozygous for *chico*, heterozygosity for a hypomorphic *Inr* allele led to a further reduction in cell number in the wing and the eye (see Table 4).

Table 4: One Mutant Copy of the *Inr* Enhances the Growth Phenotype of *chico* Mutant Cells

Wing Analysis[a]

Genotype	1 Area[b,c] ($10^6 \mu m^2$)	2 Overall size reduction (%)	3 Cell density[d] (cells/μm^2)	4 Area covered per cell[e] (μm^2)	5 Cell size reduction (%)	6 Approx. No. of cells in measured area[b,f]	7 Cell number reduction (%)
chico^2;+/+	0.96±0.03	-----	$8.0x10^{-3}$±$0.12x10^{-3}$	125±1.9	-----	7680	-----
chico^2; *Inr*^{05545}/+	0.79±0.03	17.7	$7.8x10^{-3}$±$0.09x10^{-3}$	128±1.5	0	6162	19.8

Eye Analysis[g]

Genotype	1 Eye area[c]	2 No. of ommatidia per eye	3 Area covered per ommatidium[h] (arbitrary units)
chico^2;+/+	261 896±5097	483±7	542
chico^2; *Inr*^{05545}/+	198 634±3280	411±2	483

[a] From females four wings of each genotype were analyzed.
[b] The area of the whole wing was integrated exclusive the alula and the costal cell.
[c] Measured using NIH Image 1.60.
[d] Assessed by counting number of wing hairs on the dorsal wing surface in a 10 000 μm^2 area just anterior to the PCV.
[e] Reciprocal of column 3.
[f] Generated by multiplying the values in column 1 by those in column 3.
[g] Eight eyes of each genotype were analyzed.
[h] Generated by dividing the values in column 1 by those in column 2.

Thus, in the absence of *chico* function a reduction of the receptor level potentiates the growth reduction. This CHICO independent signaling of INR is likely to be mediated by PI3K binding sites in the C-terminal tail of the INR (Yenush et al., 1996, see discussion). Similarly, expressing a catalytically inactive version of PI3K in *chico* homozygous wing discs leads to a further reduction in wing size by 48 percent (data not shown). Thus the *chico* mutant phenotype is modified by mutations in *Inr* and *PI3K*. This is consistent with the notion that INR, CHICO and PI3K form a conserved signaling pathway involved in the cell autonomous control of growth and cell size in Drosophila.

Besides of its influence on cell size and cell number, it was found that CHICO also controls lipid levels. This finding is further evidence on the relevance of *chico* in the insulin signalling pathway, since said pathway is known for its role in the control of cellular metabolism in vertebrates and in C. elegans. Thus it was investigated whether energy stores are altered in *chico* mutant flies. The fresh and dry weights of different flies were determined (Figure 5A) as well as their amounts of lipid, protein and glycogen per unit of fresh weight (Figure 5B). While there was no significant difference in levels of proteins and glycogen, lipid levels were increased significantly in *chico* males (Figure 5B). In fact, in spite of their smaller size, *chico* males had almost twice as much lipids as wild-type males per mg fresh weight. The dramatic increase in lipids in *chico* mutant males is reminiscent of hypertriglyceridemia in IRS-1 deficient mice (Abe et al., 1998) and of fat accumulation observed in C. elegans containing a mutation in the *daf-2* gene, which encodes the insulin receptor homologue (Kimura et al., 1997). Thus it appears that the INR signaling pathway controls cellular metabolism in vertebrates, nematodes and insects.

Since it could be shown that loss of function mutations in *chico*, which encodes a Drosophila homolog of IRS 1-4, cause a reduction in overall growth by reducing cell size and cell number, since it could furthermore be shown that the primary function of CHICO is to regulate overall growth by coordinating the control of cell cycle progression and cell growth and not by controlling apoptosis, and since CHICO furthermore is likely to be part of a nutritional sensing system, *chico* and its mutations are very useful tools for the investigation of e.g. the insulin signalling pathway, the screening of potential drugs for the treatment of defects in said pathway, and the screening of drug targets. *Chico* and its mutations are especially suitable tools in Drosophila mutants usable as in vitro monitory systems.

Thus, one subject of the present invention is a method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size and/or cell size and/or development time and/or lipid level is determined whereby alterations of the body size and/or cell size and/or development time and/or lipid level are detectable in at least part of the animal. In a preferred embodiment said method is a method for searching for compounds or mutations interacting directly or indirectly with CHICO involving life processes, whereby a viable *chico* mutant insect, e.g. a fly such as Drosophila, is treated with at least one compound or with at least one compound generating means, and that the effect of such treatment is detected, whereby said mutant comprises at most one wild-type *chico* gene. As already mentioned above, the animals suitable in the scope of the present invention are insects. The advantage of insects is the highly conserved insulin signaling pathway together with their

fast reproducibility. Preferably said method is performed with a Drosophila mutant, whereby said mutant is treated in the egg or larvae stadium with said compound or compound generating means. As was shown above, different easily detectable and also quite well quantifiable characteristics can be used to determine the effect of an applied treatment, such as alteration in size and/or weight and/or developmental time and/or lipid levels Of course, for many applications it is desirable that the animals used are already altered in size and/or weight and/or developmental time and/or lipid levels, so that therapeutical effects can be detected.

Mutants suitable for the method of the present invention are such ones that do not comprise a wild-type *chico* gene or that have one wild type *chico* gene. Thus the following combinations are encompassed by the present invention:

- both *chico* genes are totally lost,
- both wild-type *chico* genes are replaced by *chico* alleles with reduced CHICO activity
- both wild-type *chico* genes are replaced by *chico* alleles with no CHICO activity,
- one *chico* gene is totally lacking and one is replaced with a *chico* allele having no CHICO activity,
- one *chico* gene is totally lacking and one is replaced with a *chico* allele having reduced CHICO activity,
- one *chico* allele has no activity and one *chico* allele has reduced activity,
- one *chico* is the wild-type *chico* gene, and the second *chico* is an allele with no activity
- one *chico* is the wild-type *chico* gene, and the second *chico* is an allele with reduced CHICO activity
- one *chico* is the wild-type *chico* gene, and the second *chico* is totally lacking.

As wild-type CHICO in the scope of the present invention any protein is meant that has the same

effect as wild-type CHICO and at least about 50 % identity with the protein structure of Table 1. As wild-type *chico* any *chico* gene is referred to that encodes the amino acid sequence of Table 1 (2, 3), or that encode a protein which is sufficiently homologous to CHICO that it has the same effect in the animals of the present invention as CHICO. Relevant effects of CHICO - as it results from the above disclosure - are cell size, cell number and lipid level. Preferred DNA sequences are e.g. the genomic or the cDNA sequence represented in Table 2(SEQ. ID. NO. 4) or Table 1 (SEQ. ID. No. 1, 2).

As *chico* mutation according to the present invention any mutation is considered that has an at least reduced activity compared to the activity of the wild type animal. Preferred *chico* mutations are those having no activity and leading to size reduced homozygous animals. Such *chico* mutations are the sequences resulting in a cell number reduction of at least 10 %, preferably at least 30 %, a cell size reduction of at least about 10 %, preferably at least about 30 %,and an enhancement of the lipid content per weight unit of at least about 20 %, preferably about 50 % (all % concerning homozygous *chico* mutant animals in comparision with wild-type animals). Preferred examples for such a mutation are the mutations described as $chico^1$ and $chico^2$.

In general, total loss of *chico* activity is obtained when e.g. at least the PH domain is deleted or tyrosin residues Tyr(411) and Tyr(641)(positions referred to SEQ ID NOS 2 and 3) are substituded. Partial loss of CHICO activity is e.g. due to substitutions in the region of the PTB domain. The above mentioned alterations in *chico* are by no means complete and have to be clearly understood as non limiting examples.

The animals of the present invention can e.g. be obtained by mutagenesis procedures known to the expert. Suitable mutagens include but are not limited to P-elements, X-ray and ethylmethane sulfonate (EMS).

A suitable method for generating mutant insects comprises that adult insects, in particular males, are treated with a mutation generating means under mutation generating conditions, that thus treated insects are crossed to wild-type or mutant insects, in particular to *chico* mutant insects, and that viable offsprings with altered cell number and /or cell size and/or developmental time and/or lipid levels are cultivated under suitable conditions.

As it has been shown in the scope of the present invention, it is not necessary to generate fully mutant animals. By e.g. the eye-FLP technique, it is possible to selectively generate mutated head regions. Such partially mutated animals are advantageous for many applications, since they avoid the laborous need to generate mutated strains.

Specific and much preferred applications of the animals and the method of the present invention are the screening for compounds that are useful in the modulation, e.g. the treatment, of diabetes type 2, and the further investigation of diabetes type 2, in particular the search for further factors involved in the development of said disease. Such factors possibly involved in the development of said (but also other) disease can be found by applying a mutation generating means, in particular a mutagen such as radiation, P element, or chemical compound, to the animal under conditions suitable to generate gene defects in the factors

One very interesting application of *chico* mutant insects or insects with *chico* phenotype is connected with the fact that the insulin signaling pathway is conserved in structure and function. In mammalian cells, activation of the insulin or IGF-1 (insulin-like-growth factor-1) receptor by insulin and IGF-1, respectively, results in the recruitment of IRS-1 or IRS-2 to the receptor via interaction of the IRS PTB

domains with a phosphotyrosine motif (NPXY) in the juxtamembrane region of the receptors. Phosphorylation of multiple tyrosine residues of IRS-1 triggers the activation of various signaling pathways including the RAS/MAP kinase pathway via the SH2/SH3 adaptor GRB2, and the PI3K/PKB pathway via the p85 SH2 adaptor subunit of p110 PI3K (Yenush and White, 1997). The Drosophila INR shares many structural features with its human homologues, including its heterotetrameric structure and a conserved PTB consensus binding site in the juxtamembrane region. Although, the Drosophila INR contains a 400 amino acid C-terminal extension not found in any of the vertebrate receptors, it is nevertheless an important tool not only for screening compounds activating the insulin signalling pathway, but also for finding and/or further investigating compounds that are also members of said pathway. However, also the C terminal extension is of importance. This C-terminal tail contains three YXXM consensus binding sites for the SH2 domain of the p60 subunit of PI3K and four additional NPXY consensus PTB binding sites. The C-terminal domain is functional, since expression of a chimeric receptor consisting of the extracellular domain of the human INR and the intracellular domain of the Drosophila INR in murine 32D cells lacking endogenous IRS-1 can partially activate mammalian PI3K and S6K. In contrast, the ability of the human INR to activate PI3K in this system is strictly dependent on the coexpression of IRS-1 (Yenush et al., 1996). These findings and the identification of CHICO suggest that in e.g. Drosophila INR couples to the downstream effector PI3K in two different ways, one using docking sites in the INR C-terminal tail and the other connecting through docking sites in CHICO.

As described here, the effects on growth and cell size of *chico* mutants are remarkably similar to the phenotypes of mutations in genes encoding other components of the INR pathway in e.g. Drosophila.

Although loss of function mutations in the Drosophila *INR* gene are lethal, certain heteroallelic combinations are viable and show delayed development, reduced body size and decreased cell number (Chen et al., 1996) and cell size (this application). Expression of dominant negative or constitutively active variants of p110 PI3K in the developing wing and eye reduces or increases cell number and cell size, respectively (Leevers et al., 1996). Furthermore viable mutations in the gene encoding Drosophila Protein Kinase B (Staveley et al., 1998) cause a reduction in cell number and cell size (H.S. and E.H., unpublished results). The striking similarities between the phenotypes of *chico* and mutations in the genes encoding INR and DPKB, as well as the genetic interactions between mutations in *Inr*, *chico* and *PI3K*, show the specific role of the INR pathway in control of cell growth and cell number as a process independent of pattern formation and makes not only flies with a *chico* mutation induced phenotype a valuable in vivo monitoring system, but also flies with a *chico* mutation and at least one further mutation as described above.

Thus, the *chico* mutant animals of the present invention are an especially useful tool to investigate the insulin signaling pathway and possible pharmaceuticals to overcome defects therein, since said pathway is highly conserved from vertebrates to Drosophila, not only in regard to its structure but also to its function.

Examples

Example 1: Drosophila strains

chico^{1} is a P element insertion allele, originally called *fs(2)4*^{1} (Berg and Spradling, 1991). The P element was mapped using standard PCR with primers specific to the 3' end of the P element and to the

genomic sequence. Subsequently, the insertion site was precisely determined by sequencing the amplified PCR fragment. *chico*^{2} was derived from *chico*^{1} by mobilizing the P element. The resulting *Df(2L)flp147E* deletes the translation start site and the regulatory region of *chico* and the 3' coding sequences of *bsk*. The *bsk* mutation was complemented by insertion of a *bsk* rescue construct on the *Df(2L)flp147E* chromosome (Riesgo et al. 1996). For genetic interaction analysis we used *Dp110*^{D954A}, a dominant negative form of *p110* of Drosophila *PI3K* (Leevers et al., 1996) and *Inr*^{05545}, a P element induced hypomorphic allele (Fernandez et al., 1995). The *Dp110*^{D954A} transgene was driven by GAL4 which was expressed in the dorsal wing pouch using the MS-1096 line (Capdevila and Guerrero, 1994). The *Inr* allele is hypomorphic and recessive lethal.

Example 2: Molecular characterization of *chico*

An 11 kb genomic DNA fragment which has been described in Riesgo-Escovar et al., 1996 and encompasses the Jun kinase (*bsk*) and *chico* transcription units was used to screen a Drosophila cDNA library. From this screen, a partial cDNA (U1) for *chico* was recovered, sequenced, and used to screen an embryonic Drosophila cDNA library. Several cDNAs were isolated and partially sequenced (U2-U4). Sequence search of the Drosophila EST database with these sequences identified the EST GH02661. Sequencing of this EST clone indicated that it represents a full-length *chico* transcript that contains a consensus sequence for translation initiation (Cavener, 1987) and ends with a poly A tail 15 bp after a consensus poly-A addition signal. All cDNAs were found to encode the same transcript. The 11 kb genomic region was fully sequenced to establish the exon/intron structure of *chico*, and also its position in relation to *bsk* and *ME31B*. From a genomic phage of the region, a BamHI/ BamHI fragment was

subcloned into pBluescript, and a resection from the *bsk* side was performed to generate a 9.5 kb fragment that was subcloned into a transformation vector and used to generate a genomic rescue construct for *chico*. pWAX (described in Riesgo-Escovar et al., 1996) rescued both the phenotypes of *chico* and *bsk* separately and in a double mutant (data not shown, and Riesgo-Escovar et al., 1996).

Example 3: Weight Analysis

Body weight of individual male and female flies (n = 20) was measured with a precision scale (range 0.001 - 10 mg; Mettler ME30). Flies were reared under the same growth conditions and were age-matched (two days old) before weighing. The genotypes analyzed were the following: *y w; +/+*, *y w; chico^2/+* (heterozygotes for the synthetic null allele), *y w; chico^2/chico^2*, *y w; chico^1/+* (heterozygotes for the P element insertion allele), *y w; chico^1/chico^1* and *y w; chico^1/chico^2*.

Example 4: Clonal Analysis

chico^1 was recombined onto the FRT40 chromosome (Xu and Rubin, 1993).

Germline clones of the *chico^1* allele were generated using the autosomal dominant female-sterile technique in combination with the Flp recombinase system (Chou and Perrimon, 1996). Females of the genotype *y w; chico^1, FRT40/CyO y$^+$* were crossed with *y w hsFlp/Y; P(ovo^{D1} w$^+$) FRT40/CyO* males. Early third instar larvae were heat-shocked for 1.5 hr at 38°C. Females of the genotype *y w hsFlp/y w; chico^1 FRT40/P(ovo^{D1} w$^+$) FRT40* were selected and crossed to *chico^1/CyO y$^+$* males. The resulting progeny lacking any zygotic *chico* function and their siblings bearing the *CyO y$^+$* chromosome were analyzed.

For the generation of clones in the adult eye larvae of the genotype *y w hsFlp; chico^1 FRT40/ w$^+$ FRT40*

were subjected to a heat shock 24 - 48 hr AED for 1 hr at 37°C to induce mitotic recombination. Adults were examined for *w* clones and their corresponding twin spots (red pigmented) in the eye. Histological sections of the eyes were done as described previously (Basler and Hafen, 1988). Selective removal of *chico* function in the eye disc progenitors was achieved in animals of the genotype *y w ey-Flp; chico^1 FRT40 / P(w$^+$) 1(2)2L-3.1 FRT40* and *y w ey-Flp; chico^1 FRT40 / P(w$^+$) 1(2)2L-3.1 FRT40; P(w$^+$ chico genomic rescue construct pCSR4)/+*. The eyFlp technique has been developed by B. Dickson (personal communication).

Wing clones. Larvae of the genotype *f hsFlp/f; chico^1 FRT40/ck P(f$^+$) FRT40* were subjected to a heat shock 48 - 72 hr AED for 0.5 hr at 36°C to induce mitotic recombination. Wings were mounted and examined under a compound microscope.

Disc clones. Larvae of the genotype *y w hsFlp/y w; chico^1 FRT40/P(arm-lacZ w$^+$) FRT 40* and *y w hsFlp/y w; FRT40/P(arm-lacZ w$^+$) FRT40*, respectively were subjected to a heat shock 24 -48 hr AED for 0.5 hr at 32°C to induce mitotic recombination at a low frequency. Larvae at late third instar stage were dissected. Discs were fixed and permeabilized and stained with appropriate antibodies. Antibodies were: rabbit anti-β-Gal (1/2000) and FITC- or TR-conjugated secondary antibodies (1/200). Actin filaments were stained using phalloidin-TR (Molecular Probes).

Example 5: TUNEL Assay

Apoptotic cells were detected using the ApopTag system (ONCOR). Clones in larvae of the genotype *y w hsFlp/y w; chico^1 FRT40/P(arm-lacZ w$^+$) FRT 40* and *y w hsFlp/y w; FRT40/P(arm-lacZ w$^+$) FRT40*, respectively, and *y w hsFlp/y w; chico^1 FRT40/P(arm-lacZ w$^+$) M(2L)Z FRT 40* and *y w hsFlp/y w; FRT40/P(arm-lacZ w$^+$) M(2L)Z FRT40*, respectively, were induced as described above. Larvae at

late third instar stage were dissected. Discs were fixed and stained as described above. 3'-OH ends of DNA were labelled for 0.5 hr at 37°C by addition of digoxigenin 11-UTPs by the enzyme TdT and subsequently detected with FITC-conjugated anti-digoxigenin antibody. Discs of *GMR-grim* larvae, kindly provided by John Abrams (University of Texas), were used as positive controls.

Example 6: Flow Cytometry

Female larvae of the genotype $chico^2/+$ and $chico^2/chico^2$, respectively, were dissected at late third instar stage (non-wandering stage). Dissociation of wing discs was done as described in Neufeld et al., 1998. Approximately 20 discs were dissociated. The cell suspension was analyzed using a Becton Dickinson FACStar^{Plus} and the data was analyzed using Cell Quest (Becton Dickinson).

Example 7: Metabolic Studies

Adult males (n = 10) of the genotypes $chico^2/chico^2$, $chico^2/+$ and +/+ were collected 3 days after eclosion. The fresh and dry weight, respectively, from individual males was determined. To determine the dry weight, males were fixed in 100% ethanol for 10 minutes at 90°C and then dried for 2 hr at 110°C. Protein data were obtained through Kjeldahl digestion and subsequent Nesslerization (Minari and Zliversmit, 1963), with total nitrogen converted to protein by using a factor of 6.25. Glycogen and lipid data were obtained as described in van Handel and Day, 1988.

While there are shown and described presently preferred embodiments of the invention, it is to be distinctly understood that the invention is not limited thereto but may be otherwise variously embodied and practiced within the scope of the following claims.

Literature

Abe, H., Yamada, N., Kamata, K., Kuwaki, T., Shimada, M., Osuga, J., Shionoiri, F., Yahagi, N., Kadowaki, T., Tamemoto, H., Ishibashi, S., Yazaki, Y., and Makuuchi, M. (1998). Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J. Clin. Invest. *101*, 1784-1788.

Basler, K. and Hafen, E. (1988). Control of photoreceptor cell fate by the sevenless protein requires a functional tyrosine kinase domain. Cell *54*, 299-312.

Berg, C. A. and Spradling, A. C. (1991). Studies on the rate and site-specificity of P-element transposition. Genetics *127*, 515-524.

Bryant, P. J. and Simpson, P. (1984). Intrinsic and extrinsic control of growth in developing organs. Quarterly Review of Biology *59*, 387-415.

Capdevila, J. and Guerrero, I. (1994). Targeted expression of the signaling molecule decapentaplegic induces pattern duplications and growth alterations in Drosophila wings. EMBO J. *13*, 4459-4468.

Cavener, D. R. (1987). Comparison of the consensus sequence flanking translational start sites in Drosophila and vertebrates. Nucl. Acids Res. *15*, 1353-1361.

Chen, C., Jack, J., and Garofalo, R. S. (1996). The Drosophila insulin receptor is required for normal growth. Endocrinology *137*, 846-856.

Chou, T. B. and Perrimon, N. (1996). The autosomal FLP-DFS technique for generating germline mosaics in Drosophila melanogaster. Genetics *144*, 1673-1679.

Conlon, I. and Raff, M. (1999). Size control in animal development. Cell *96*, 235-244.

de Valoir, T., Tucker, M. A., Belikoff, E. J., Camp, L. A., Bolduc, C., and Beckingham, K. (1991). A second maternally expressed Drosophila gene encodes a putative RNA helicase of the "DEAD box" family. Proc. Natl. Acad. Sci. USA *88*, 2113-2117.

Edgar, B. A., Lehman, D. A., and O'Farrell, P. H. (1994). Transcriptional regulation of string (cdc25): A link between developmental programming and the cell cycle. Development *120*, 3131-3143.

Fernandez, R., Tabarini, D., Azpiazu, N., Frasch, M., and Schlessinger, J. (1995). The Drosophila insulin receptor homolog: a gene essential for embryonic development encodes two receptor isoforms with different signaling potential. EMBO J. *14*, 3373-3384.

Gallant, P., Shiio, Y., Cheng, P. F., Parkhurst, S. M., and Eisenman, R. N. (1996). Myc and Max homologs in Drosophila. Science *274*, 1523-1527.

Kimura, K. D., Tissenbaum, H. A., Liu, Y., and Ruvkun, G. (1997). daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science *277*, 942-946.

Leevers, S. J., Weinkove, D., MacDougall, L. K., Hafen, E., and Waterfield, M. D. (1996). The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J. *15*, 6584-6594.

Minari, O. and Zliversmit, D. B. (1963). Use of KCN for stabilization of color in direct Nesslerization of Kjeldahl digests. Anal. Biochem. *6*, 320-327.

Morata, G. and Ripoll, P. (1975). Minutes: Mutants of Drosophila autonomously affecting cell division rate. Dev. Biol. *42*, 211-221.

Neufeld, T. P., Delacruz, A. F. A., Johnston, L. A., and Edgar, B. A. (1998). Coordination of Growth and Cell Division in the Drosophila Wing. Cell *93*, 1183-1193.

Olivier, J. P., Raabe, T., Henkemeyer, M., Dickson, B., Mbamalu, G., Margolis, B., Schlessinger, J., Hafen, E., and Pawson, T. (1993). A Drosophila SH2-SH3 adaptor protein implicated in coupling the sevenless tyrosine kinase to an activator of Ras guanine nucleotide exchange, Sos. Cell *73*, 179-191.

Quiring, R., Walldorf, U., Kloter, U., and Gehring, W. J. (1994). Homology of the eyeless gene of Drosophila to the Small eye gene in mice and Aniridia in humans. Science *265*, 785-789.

Riddle, D. L. (1988). The dauer larva. In The nematode Caenorhabditis elegans, W. N. Wood, ed. (Cold Spring Harbor: Cold Spring Harbor Laboratory Press) 393-412.

Riesgo-Escovar, J. R., Jenni, M., Fritz, A., and Hafen, E. (1996). The *Drosophila* Jun-N-terminal kinase is required for cell morphogenesis but not for DJun-dependent cell fate specification in the eye. Genes Dev. *10*, 2759-2768.

Robertson, F. W. (1963). The ecological genetics of growth in Drosophila. VI. The genetic correlation between the duration of the larval period and body size in relation to larval diet. *4*, 74-92.

Santamaria, P. (1983). Analysis of haploid mosaics in Drosophila. Dev. Biol. *96*, 285-295.

Simpson, P. (1979). Parameters of cell competition in the compartments of the wing disc of Drosophila. Dev. Biol. *69*, 182-193.

Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W. G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R. J., Neel, B. G., Birge, R. B., Fajardo, J. E., Chou, M. M., Hanafusa, H., Schaffhausen, B., and Cantley, L. C. (1993). SH2 domains recognize specific phosphopeptide sequences. Cell *72*, 767-778.

Staveley, B. E., Ruel, L., Jin, J., Stambolic, V., Mastronardi, F. G., Heitzler, P., Woodgett, J. R., and Manoukian, A. S. (1998). Genetic analysis of protein kinase B (AKT) in Drosophila. Curr. Biol. *8*, 599-602.

Stewart, C. E. and Rotwein, P. (1996). Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiological Reviews *76*, 1005-1026.

Thomas, G. and Hall, M. N. (1997). TOR signalling and control of cell growth. Curr. Opin. Cell Biol. *9*, 782-787.

van Handel, E. and Day, J. F. (1988). Assay of lipids, glycogen and sugars in individual mosquitoes: correlations with wing length in field-collected Aedes vexans. J. Amer. Mosq. Contr. Assoc. *4*, 549-550.

Weigmann, K., Cohen, S. M., and Lehner, C. F. (1997). Cell cycle progression, growth and patterning in imaginal discs despite inhibition of cell division after inactivation of Drosophila Cdc2 kinase. Development *124*, 3555-3563.

Weinkove, D., Leevers, S. J., MacDougall, L. K., and Waterfield, M. D. (1997). p60 is an adaptor for the Drosophila phosphoinositide 3-kinase, Dp110. J. Biol. Chem. *272*, 14606-14610.

Xu, T. and Rubin, G. M. (1993). Analysis of genetic mosaics in developing and adult *Drosophila* tissues. Development *117*, 1223-1237.

Yenush, L., Fernandez, R., Myers, M. G., Jr., Grammer, T. C., Sun, X. J., Blenis, J., Pierce, J. H., Schlessinger, J., and White, M. F. (1996). The Drosophila insulin receptor activates multiple signaling pathways but requires insulin receptor substrate proteins for DNA synthesis. Mol. Cell. Biol. *16*, 2509-2517.

Yenush, L. and White, M. F. (1997). The IRS-signalling system during insulin and cytokine action. Bioessays *19*, 491-500.

Claims

1. A method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable chico mutant insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size and/or cell size and/or development time and/or lipid level is determined whereby alterations of the body size and/or cell size and/or development time and/or lipid level are detectable in at least part of the animal.

2. The method of claim 1 characterized in that the viable chico mutant insect comprises at most one wild-type *chico* gene.

3. The method of claim 2 wherein the mutant is a Drosophila mutant and wherein said mutant is treated in the egg or larvae stadium with said compound or compound generating means.

4. The method of claim 2 or 3 wherein the mutant does not comprise a wild-type *chico* gene.

5. The method of claim 2 or 3 wherein the Drosophila mutant comprises one wild-type *chico* gene.

6. The method of claim 5 wherein the wild-type *chico* gene encodes the amino acid sequence of Table 1 (SEQ. ID. NO. 2, 3).

7. The method of claim 6, wherein the wild-type *chico* gene is the genomic or the cDNA sequence represented in Table 1 (SEQ. ID. NO. 1, 2) or Table 2 (SEQ. ID. NO. 4).

8. The method of anyone of claims 2 to 7 wherein the Drosophila mutant comprises at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

9. The method of claim 7 wherein the *chico* mutation is the mutation described in Figure 3A.

10. The method of anyone of claims 2 to 9 wherein the Drosophila lacks at least one *chico* gene.

11. The method of claim 10 wherein the mutant lacks both *chico* genes.

12. The method of anyone of claims 1 to 11 wherein the compound is a compound for the treatment of diabetes type 2.

13. The method of anyone of claims 1 to 12, wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the whole animal.

14. The method of anyone of claims 1 to 12, wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the head region only.

15. A viable insect mutant comprising at most one wild-type *chico* gene in at least a part of its body and said at least one part of the body shows reduced size.

16. The mutant of claim 15 that does not comprise as sole *chico* genes two $chico^1$ genes.

17. The mutant of claim 15 or 16 that does not comprise a wild-type *chico* gene.

18. The mutant of claim 15 or 16 that comprises one wild-type *chico* gene.

19. The mutant of claim 18 wherein the wild-type *chico* gene encodes the amino acid sequence of Table 1 (SEQ. ID. NO. 2, 3).

20. The mutant of claim 19, wherein the wild-type *chico* gene is the genomic or the cDNA sequence represented in Table 2 (SEQ. ID. NO. 4) or Table 1 (SEQ. ID. NO. 1, 2).

21. The mutant of anyone of claims 15 to 20 comprising at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

22. The mutant of claim 21 wherein the *chico* mutation is the mutation described in Figure 3A.

23. The mutant of anyone of claims 15 to 22 lacking at least one *chico* gene.

24. The mutant of claim 15 lacking both *chico* genes.

25. The mutant of anyone of claims 15 to 24 which is a fly mutant, in particular a Drosophila mutant.

26. The mutant of anyone of claims 15 to 25, wherein at most one wild-type *chico* gene is found in the whole body of the insect.

27. The mutant of anyone of claims 15 to 25, wherein at most one wild-type *chico* gene is found in the head region of the insect only.

28. Use of an insect according to anyone of claims 15 to 27 as a means in screening compounds for modulating diseases.

29. Use of an insect according to anyone of claims 15 to 27 as a means for searching for mutations involved directly or indirectly in the insulin signaling pathway.

30. Use according to claim 22 or 23, characterized in that the disease is diabetes type 2.

31. A method for generating a mutant insect, characterized in that adult animals, in particular males, are treated with a mutation generating means under mutation generating conditions, that thus treated insects are crossed to wild-type or mutant insects, in particular *chico* mutant insects, and that viable offsprings with altered cell number and /or cell size and/or developmental time and/or lipid levels are cultivated under suitable conditions.



Figure 1A



Figure 1B



Figure 2A



Figure 2B



Figure 2C


ME31B
chico
fs(2)4'
3'
5'
bsk
Met
Stop
H
E
H
H
E E
H
HE
0
1
2
3
4
5
6
7
8
9
10
11
kb
distal
pWAX rescue construct
pWZ bsk rescue construct
pCSR4 chico rescue construct
3'
Df(2L)flp 147E
Deficiency Chromosome

Figure 3A

MASISDDGMALSGYLKKLKTMKKKFFVLYEETSTSAARLEYYDTEKKFLQRAEPKRVIYLKNCFN
INRRLDTKHRFVIVLSSRDGGFGIVLENENDLRKWLDKLLVLQRNIANSNGTAHSPYDHVWQVVI
QKKGISEKVGITGTYHCCLTSKSLTFVCIGPEKTPNGEDRVASIEILLTTIRRCGHASPQCIFYV
ELGRQSVLGSGDLWMETDNAAIATNMHNTILSAMSAKTESNTNLINV**YQN**RPDLSHEPMRKRSSS
ANEASKPINVNVIQNSQNSLELRSCSSPHNYGFGRERCDSLPTRNGTLSESSNQTYFGSNHGLRS
NTISGIRPHSTNKHSNSPTFTMPLRCSESEESSISVDESDDNGSFSHYRLNTRSSETAIPEENID
DFASAELFSKVTEQNVSDEN**YIPM**NPVNPTDAIHEKEKADMQRLEDASLHFNFPEHASEKLAKDF
DLDSDNQCCRPIRAYSIGNKVEHLKFNKRLGHLNDTGQNPNRVRAYSVGSKSKIPRCDLQRVVLV
EDNKHEFTANRSQSSITKEGTSYGSSANRQKKSTSAPLLSLKNQINSDRMSDLMEIDFSQATNLE
KQKFIKNNEIPKYIENVFPKAPRTDSSSLTLHATSQKDIFNGTKLNNTAITSEDG**YLEM**KPVGNG
YTPSSNCLPMKVERLKLSDYQTAPPITATAAPVHDLNKISTYNISAEKWREQPSRSEEKKSNSPL
NDNTFGLKPTNVESTSKSHDVHSANQIDSEKVCAQSSDKLNNLADKIVENNNLDIGGHEEKKLVH
SISSEDYTQIKDKSNDFTKFNEAGYKILQIKSDSSLISSKLYQKGIHKDNLERSQRLTESVNTIP
DNATATAVSSSSLTKFNINSAKPAAAADSRSTGTDPSTPQNILQIKDLNFPSRSSSRISQPELHY
ASLDLPHCSGQNPAKYLKRGSRESPPVSACPEDGNTYAKIDFDQSDSSSSSSNIFNTZ

Figure 3B



Figure 3C



Figure 4A



Figure 4B

Figure 4C


weight (mg)
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
fresh weight
dry weight
+/+
+/-
-/-
genotype

Figure 5A


lipid
protein
glycogen
cal/mg fresh weight
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0
+/+
+/-
-/-
genotype

Figure 5B

DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "**IN VIVO INSECT MODEL SYSTEM FOR TYPE-2 DIABETES,**" the specification of which (check one): ☐ is attached hereto; ☒ was filed on December 20, 2001 as Application Serial No. 10/019,098; ☒ was filed as PCT International Application No. PCT/IB99/01166 on June 22, 1999. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

			Priority Claimed	
			☐	☐
(Application Serial Number)	(Country)	(Day/Month/Year Filed)	Yes	No
			☐	☐
(Application Serial Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below:

(Application Serial Number)	(Day/Month/Year Filed)
(Application Serial Number)	(Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PCT/IB99/01166	June 22, 1999	Pending
(Application Serial Number)	(Day/Month/Year Filed)	(Status-Patented, Pending or Abandoned)
(Application Serial Number)	(Day/Month/Year Filed)	(Status-Patented, Pending or Abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

APPLICABLE RULES AND STATUTES

37 CFR 1.56. DUTY OF DISCLOSURE - INFORMATION MATERIAL TO PATENTABILITY (Applicable Portion)

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

(1) prior art cited in search reports of a foreign patent office in a counterpart application, and
(2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentability defines, to make sure that any material information contained therein is disclosed to the Office.

Information relating to the following factual situations enumerated in 35 USC 102 and 103 may be considered material under 37 CFR 1.56(a).

35 U.S.C. 102. CONDITIONS FOR PATENTABILITY: NOVELTY AND LOSS OF RIGHT TO PATENT

A person shall be entitled to a patent unless --

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent, or

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or

(c) he has abandoned the invention, or

(d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months before the filing of the application in the United States, or

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraph (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent, or

(f) he did not himself invent the subject matter sought to be patented, or

(g) before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.

35 U.S.C. 103. CONDITIONS FOR PATENTABILITY; NON-OBVIOUS SUBJECT MATTER (Applicable Portion)

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

35 U.S.C. 112. SPECIFICATION (Applicable Portion)

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

POWER OF ATTORNEY: I hereby appoint as my attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

John B. Lungmus(18,566)	Richard B. Hoffman(26,910)	Robert M. Gerstein (34,824)	Michael R. Weiner (38,359)
Allen H. Gerstein (22,218)	James P. Zeller (28,491)	Michael R. Hull (35,902)	David C. Read (39,811)
Nate F. Scarpelli (22,320)	Kevin D. Hogg (31,839)	Anthony G. Sitko (36,278)	Thomas A. Miller (40,091)
Michael F. Borun (25,447)	Jeffrey S. Sharp (31,879)	James A. Flight (37,622)	William K. Merkel (40,725)
Carl E. Moore, Jr. (26,487)	Martin J. Hirsch (32,237)	Roger A. Heppermann (37,641)	Sandip H. Patel (43,848)
Richard H. Anderson (26,526)	Richard M. La Barge (32,254)	David A. Gass (38,153)	Kevin M. Flowers (44,684)
Patrick D. Ertel (26,877)	James J. Napoli (32,361)	Gregory C. Mayer (38,238)	William J. Kramer (46,229)

Send correspondence to: Jeffrey S. Sharp

FIRM NAME	PHONE NO.	STREET	CITY & STATE	ZIP CODE
Marshall, Gerstein & Borun	312-474-6300	6300 Sears Tower 233 South Wacker Drive	Chicago, Illinois	60606-6357

Full Name of First or Sole Inventor Ernst Hafen	Citizenship Swiss
Residence Address - Street Zoologisches Institut/Winterthurerstrasse 190	Post Office Address - Street Zoologisches Institut/Winterthurerstrasse 190
City (Zip) CH-8057 Zürich CHX	City (Zip) CH-8057 Zürich
State or Country Switzerland	State or Country Switzerland
Date ☒ 13.03.02	Signature ☒

SEQUENCE LISTING

<110> Universitaet Zuerich

<120> In vivo model system for type-2 diabetes

<130> Universitaet Zuerich

<140>
<141>

<160> 4

<170> PatentIn Ver. 2.1

<210> 1
<211> 2907
<212> DNA
<213> Dosophila melanogaster

<400> 1
atggcatcaa tatcggatga cggcatggcg ctgagtggct acctcaagaa gctgaagacc 60

atgaagaaga agttctttgt gctgtacgag gagacgagca cttcggcagc ccggctggag 120

tactacgata ccgaaaagaa gttcctgcaa agagccgagc caaaaagggt tatatatctg 180

aagaattgct tcaacatcaa tcgccgtttg gacaccaagc atagatttgt cattgtgctc 240

tcctccagag acggtggatt cggcatcgtt ctcgagaacg aaaatgattt acgcaaatgg 300

ttggacaaac tactagttct acaaaggaac atagccaatt cgaatggaac agcgcactca 360

ccttatgacc acgtttggca agttgtcatt caaaagaagg gtatttcgga gaaagttgga 420

atcaccggaa cctaccactg ttgccttact tcaaaatccc tgacattcgt gtgcattgga 480

ccggagaaga cgcccaatgg cgaggatcgc gttgcgagca ttgaaatact tttgaccacg 540

atcaggcgat gcggtcatgc atccccacaa tgtatattct acgtggaact tggccgccaa 600

agtgtcttgg gatctggtga tctgtggatg gagacggata acgcagctat tgctactaat 660

atgcacaaca cgatactgag cgctatgtca gccaaaacag agtcgaacac gaatttaata 720

aacgtttatc agaatagacc tgacttaagt cacgagccca tgagaaagcg atcgtcgtct 780

gcaaacgaag catcgaagcc gataaacgta aatgtcatac aaaatagtca aaactctctc 840

gaattgcgca gctgcagttc gccccataac tatggtttcg gcagagagag atgcgatagc 900

ttaccaacca gaaatggaac cctaagcgag tccagcaatc aaacgtactt tggttccaac 960

catggactgc gatccaatac tatatctggc atccgtccgc actcaaccaa caagcatagt 1020

aatagtccaa cgttcaccat gccattaaga tgctcagaat ccgaagagtc atcaattagt 1080

gtcgatgaat ccgacgacaa cggcagtttt agccactaca gattaaacac gcggtcatct 1140

gagacggcaa ttcctgagga aaacattgat gactttgcca gtgcggaatt atttagcaaa 1200

gtcaccgaac aaaatgtaag tgacgaaaac tacataccga tgaatccagt caatcctacc 1260

gatgctatcc atgaaaagga gaaggctgat atgcagagat tggaagatgc ttcgctgcat 1320

ttcaactttc cggagcacgc gtcggaaaag cttgctaagg attttgatct ggactctgat 1380

aaccaatgct gtcgtcccat tcgcgcctat tcgataggca acaaggttga gcatttaaag 1440

tttaataagc gcctgggaca cttgaatgat acgggacaga atccgaatcg cgtgcgagcc 1500

tactcggttg gctccaaatc gaagataccg cgctgcgacc tgcagcgagt ggtcctcgtg 1560

gaggacaata aacatgagtt cacagcgaat aggagtcaga gtagcattac caaggaagga 1620

accagctatg gcagcagtgc caatcgacaa aagaagtcca caagtgctcc actcctcagt 1680

ctgaagaacc agataaactc cgaccgaatg agtgacttaa tggaaattga tttttcacaa 1740

gcaaccaatt tggaaaagca gaagttcatc aagaataatg aaattccgaa atacattgaa 1800

aacgtgttcc caaaagcccc gcgaacggat agctccagcc taactctgca cgccacaagt 1860

caaaaggaca ttttcaatgg caccaaacta ataacactg cgatcacatc cgaggatggt 1920

tacctcgaga tgaagccagt cggtaatgga tacactccca gttcgaattg cctgccaatg 1980

aaagtggaga aactcaagct atccgactat cagacagcac cgccactcac cgcaacagcc 2040

gcaccagtgc acgatttaaa caaaattagc acatacaata tatccgctga gaaatggaga 2100

gaacagccca gcagaagcga ggaaaagaag tcgaactcgc cattgaatga caacaccttt 2160

agctcgaaac ccacaaatgt cgagagtaca agcaaaagcc atgatgttca ttcagcaaat 2220

caaattgatt gcgagaaagt gtgcgcgcag agcagcgata agctaaataa tcatctggcc 2280

gacaagattg tcgagaacaa caatttggat ataggcgggc atgaggaaaa gaagttggtt 2340

cattcgataa gcagcgaaga ctacacacaa atcaaggaca aatcgaatga tttcacaaaa 2400

tttaacgaag ccggctacaa aattctgcaa attaaaagcg acagctcact catctcatcg 2460

aagctatacc aaaagggtat acacaaggat aacttggagc gttcgcagag acttacagag 2520

agtgtgaata cgattcccga taatgccacc gccaccgcgg tgagcagcag ctcactcacc 2580

aaattcaata taaattcagc aaagccagcc gccgccgccg attcgcgtag cactggcaca 2640

gatccaagta caccacagaa cattctacag attaaagatt tgaatttccc ctcaaggtcg 2700

tcgtctcgca tatcccagcc ggagctgcac tacgccagcc tagatcttcc ccattgcagt 2760

ggccaaaatc cagctaaata cctgaagaga ggatcacgcg aatcgccgcc ggtgtccgca 2820

tgcccggagg atgggaatac ctatgcgaaa atcgactttg accaatccga ctcctcttcc 2880

tcctcatcga acatatttaa tacgtaa 2907

<210> 2
<211> 2907
<212> DNA
<213> Dosophila melanogaster

<220>
<221> CDS
<222> (1)..(2907)

<400> 2

atg gca tca ata tcg gat gac ggc atg gcg ctg agt ggc tac ctc aag 48
Met Ala Ser Ile Ser Asp Asp Gly Met Ala Leu Ser Gly Tyr Leu Lys
1 5 10 15

aag ctg aag acc atg aag aag aag ttc ttt gtg ctg tac gag gag acg 96
Lys Leu Lys Thr Met Lys Lys Lys Phe Phe Val Leu Tyr Glu Glu Thr
20 25 30

agc act tcg gca gcc cgg ctg gag tac tac gat acc gaa aag aag ttc 144
Ser Thr Ser Ala Ala Arg Leu Glu Tyr Tyr Asp Thr Glu Lys Lys Phe
35 40 45

ctg caa aga gcc gag cca aaa agg gtt ata tat ctg aag aat tgc ttc 192
Leu Gln Arg Ala Glu Pro Lys Arg Val Ile Tyr Leu Lys Asn Cys Phe

```
    50                  55                  60

aac atc aat cgc cgt ttg gac acc aag cat aga ttt gtc att gtg ctc   240
Asn Ile Asn Arg Arg Leu Asp Thr Lys His Arg Phe Val Ile Val Leu
 65                  70                  75                  80

tcc tcc aga gac ggt gga ttc ggc atc gtt ctc gag aac gaa aat gat   288
Ser Ser Arg Asp Gly Gly Phe Gly Ile Val Leu Glu Asn Glu Asn Asp
                 85                  90                  95

tta cgc aaa tgg ttg gac aaa cta cta gtt cta caa agg aac ata gcc   336
Leu Arg Lys Trp Leu Asp Lys Leu Leu Val Leu Gln Arg Asn Ile Ala
            100                 105                 110

aat tcg aat gga aca gcg cac tca cct tat gac cac gtt tgg caa gtt   384
Asn Ser Asn Gly Thr Ala His Ser Pro Tyr Asp His Val Trp Gln Val
        115                 120                 125

gtc att caa aag aag ggt att tcg gag aaa gtt gga atc acc gga acc   432
Val Ile Gln Lys Lys Gly Ile Ser Glu Lys Val Gly Ile Thr Gly Thr
    130                 135                 140

tac cac tgt tgc ctt act tca aaa tcc ctg aca ttc gtg tgc att gga   480
Tyr His Cys Cys Leu Thr Ser Lys Ser Leu Thr Phe Val Cys Ile Gly
145                 150                 155                 160

ccg gag aag acg ccc aat ggc gag gat cgc gtt gcg agc att gaa ata   528
Pro Glu Lys Thr Pro Asn Gly Glu Asp Arg Val Ala Ser Ile Glu Ile
                165                 170                 175

ctt ttg acc acg atc agg cga tgc ggt cat gca tcc cca caa tgt ata   576
Leu Leu Thr Thr Ile Arg Arg Cys Gly His Ala Ser Pro Gln Cys Ile
            180                 185                 190

ttc tac gtg gaa ctt ggc cgc caa agt gtc ttg gga tct ggt gat ctg   624
Phe Tyr Val Glu Leu Gly Arg Gln Ser Val Leu Gly Ser Gly Asp Leu
        195                 200                 205

tgg atg gag acg gat aac gca gct att gct act aat atg cac aac acg   672
Trp Met Glu Thr Asp Asn Ala Ala Ile Ala Thr Asn Met His Asn Thr
    210                 215                 220

ata ctg agc gct atg tca gcc aaa aca gag tcg aac acg aat tta ata   720
Ile Leu Ser Ala Met Ser Ala Lys Thr Glu Ser Asn Thr Asn Leu Ile
225                 230                 235                 240

aac gtt tat cag aat aga cct gac tta agt cac gag ccc atg aga aag   768
Asn Val Tyr Gln Asn Arg Pro Asp Leu Ser His Glu Pro Met Arg Lys
```

245 250 255

cga tcg tcg tct gca aac gaa gca tcg aag ccg ata aac gta aat gtc 816
Arg Ser Ser Ser Ala Asn Glu Ala Ser Lys Pro Ile Asn Val Asn Val
260 265 270

ata caa aat agt caa aac tct ctc gaa ttg cgc agc tgc agt tcg ccc 864
Ile Gln Asn Ser Gln Asn Ser Leu Glu Leu Arg Ser Cys Ser Ser Pro
275 280 285

cat aac tat ggt ttc ggc aga gag aga tgc gat agc tta cca acc aga 912
His Asn Tyr Gly Phe Gly Arg Glu Arg Cys Asp Ser Leu Pro Thr Arg
290 295 300

aat gga acc cta agc gag tcc agc aat caa acg tac ttt ggt tcc aac 960
Asn Gly Thr Leu Ser Glu Ser Ser Asn Gln Thr Tyr Phe Gly Ser Asn
305 310 315 320

cat gga ctg cga tcc aat act ata tct ggc atc cgt ccg cac tca acc 1008
His Gly Leu Arg Ser Asn Thr Ile Ser Gly Ile Arg Pro His Ser Thr
325 330 335

aac aag cat agt aat agt cca acg ttc acc atg cca tta aga tgc tca 1056
Asn Lys His Ser Asn Ser Pro Thr Phe Thr Met Pro Leu Arg Cys Ser
340 345 350

gaa tcc gaa gag tca tca att agt gtc gat gaa tcc gac gac aac ggc 1104
Glu Ser Glu Glu Ser Ser Ile Ser Val Asp Glu Ser Asp Asp Asn Gly
355 360 365

agt ttt agc cac tac aga tta aac acg cgg tca tct gag acg gca att 1152
Ser Phe Ser His Tyr Arg Leu Asn Thr Arg Ser Ser Glu Thr Ala Ile
370 375 380

cct gag gaa aac att gat gac ttt gcc agt gcg gaa tta ttt agc aaa 1200
Pro Glu Glu Asn Ile Asp Asp Phe Ala Ser Ala Glu Leu Phe Ser Lys
385 390 395 400

gtc acc gaa caa aat gta agt gac gaa aac tac ata ccg atg aat cca 1248
Val Thr Glu Gln Asn Val Ser Asp Glu Asn Tyr Ile Pro Met Asn Pro
405 410 415

gtc aat cct acc gat gct atc cat gaa aag gag aag gct gat atg cag 1296
Val Asn Pro Thr Asp Ala Ile His Glu Lys Glu Lys Ala Asp Met Gln
420 425 430

aga ttg gaa gat gct tcg ctg cat ttc aac ttt ccg gag cac gcg tcg 1344
Arg Leu Glu Asp Ala Ser Leu His Phe Asn Phe Pro Glu His Ala Ser

435 440 445

gaa aag ctt gct aag gat ttt gat ctg gac tct gat aac caa tgc tgt 1392
Glu Lys Leu Ala Lys Asp Phe Asp Leu Asp Ser Asp Asn Gln Cys Cys
450 455 460

cgt ccc att cgc gcc tat tcg ata ggc aac aag gtt gag cat tta aag 1440
Arg Pro Ile Arg Ala Tyr Ser Ile Gly Asn Lys Val Glu His Leu Lys
465 470 475 480

ttt aat aag cgc ctg gga cac ttg aat gat acg gga cag aat ccg aat 1488
Phe Asn Lys Arg Leu Gly His Leu Asn Asp Thr Gly Gln Asn Pro Asn
485 490 495

cgc gtg cga gcc tac tcg gtt ggc tcc aaa tcg aag ata ccg cgc tgc 1536
Arg Val Arg Ala Tyr Ser Val Gly Ser Lys Ser Lys Ile Pro Arg Cys
500 505 510

gac ctg cag cga gtg gtc ctc gtg gag gac aat aaa cat gag ttc aca 1584
Asp Leu Gln Arg Val Val Leu Val Glu Asp Asn Lys His Glu Phe Thr
515 520 525

gcg aat agg agt cag agt agc att acc aag gaa gga acc agc tat ggc 1632
Ala Asn Arg Ser Gln Ser Ser Ile Thr Lys Glu Gly Thr Ser Tyr Gly
530 535 540

agc agt gcc aat cga caa aag aag tcc aca agt gct cca ctc ctc agt 1680
Ser Ser Ala Asn Arg Gln Lys Lys Ser Thr Ser Ala Pro Leu Leu Ser
545 550 555 560

ctg aag aac cag ata aac tcc gac cga atg agt gac tta atg gaa att 1728
Leu Lys Asn Gln Ile Asn Ser Asp Arg Met Ser Asp Leu Met Glu Ile
565 570 575

gat ttt tca caa gca acc aat ttg gaa aag cag aag ttc atc aag aat 1776
Asp Phe Ser Gln Ala Thr Asn Leu Glu Lys Gln Lys Phe Ile Lys Asn
580 585 590

aat gaa att ccg aaa tac att gaa aac gtg ttc cca aaa gcc ccg cga 1824
Asn Glu Ile Pro Lys Tyr Ile Glu Asn Val Phe Pro Lys Ala Pro Arg
595 600 605

acg gat agc tcc agc cta act ctg cac gcc aca agt caa aag gac att 1872
Thr Asp Ser Ser Ser Leu Thr Leu His Ala Thr Ser Gln Lys Asp Ile
610 615 620

ttc aat ggc acc aaa cta aat aac act gcg atc aca tcc gag gat ggt 1920
Phe Asn Gly Thr Lys Leu Asn Asn Thr Ala Ile Thr Ser Glu Asp Gly

625 630 635 640

tac ctc gag atg aag cca gtc ggt aat gga tac act ccc agt tcg aat 1968
Tyr Leu Glu Met Lys Pro Val Gly Asn Gly Tyr Thr Pro Ser Ser Asn
645 650 655

tgc ctg cca atg aaa gtg gag aaa ctc aag cta tcc gac tat cag aca 2016
Cys Leu Pro Met Lys Val Glu Lys Leu Lys Leu Ser Asp Tyr Gln Thr
660 665 670

gca ccg cca ctc acc gca aca gcc gca cca gtg cac gat tta aac aaa 2064
Ala Pro Pro Leu Thr Ala Thr Ala Ala Pro Val His Asp Leu Asn Lys
675 680 685

att agc aca tac aat ata tcc gct gag aaa tgg aga gaa cag ccc agc 2112
Ile Ser Thr Tyr Asn Ile Ser Ala Glu Lys Trp Arg Glu Gln Pro Ser
690 695 700

aga agc gag gaa aag aag tcg aac tcg cca ttg aat gac aac acc ttt 2160
Arg Ser Glu Glu Lys Lys Ser Asn Ser Pro Leu Asn Asp Asn Thr Phe
705 710 715 720

agc tcg aaa ccc aca aat gtc gag agt aca agc aaa agc cat gat gtt 2208
Ser Ser Lys Pro Thr Asn Val Glu Ser Thr Ser Lys Ser His Asp Val
725 730 735

cat tca gca aat caa att gat tgc gag aaa gtg tgc gcg cag agc agc 2256
His Ser Ala Asn Gln Ile Asp Cys Glu Lys Val Cys Ala Gln Ser Ser
740 745 750

gat aag cta aat aat cat ctg gcc gac aag att gtc gag aac aac aat 2304
Asp Lys Leu Asn Asn His Leu Ala Asp Lys Ile Val Glu Asn Asn Asn
755 760 765

ttg gat ata ggc ggg cat gag gaa aag aag ttg gtt cat tcg ata agc 2352
Leu Asp Ile Gly Gly His Glu Glu Lys Lys Leu Val His Ser Ile Ser
770 775 780

agc gaa gac tac aca caa atc aag gac aaa tcg aat gat ttc aca aaa 2400
Ser Glu Asp Tyr Thr Gln Ile Lys Asp Lys Ser Asn Asp Phe Thr Lys
785 790 795 800

ttt aac gaa gcc ggc tac aaa att ctg caa att aaa agc gac agc tca 2448
Phe Asn Glu Ala Gly Tyr Lys Ile Leu Gln Ile Lys Ser Asp Ser Ser
805 810 815

ctc atc tca tcg aag cta tac caa aag ggt ata cac aag gat aac ttg 2496
Leu Ile Ser Ser Lys Leu Tyr Gln Lys Gly Ile His Lys Asp Asn Leu

```
            820                 825                 830

gag cgt tcg cag aga ctt aca gag agt gtg aat acg att ccc gat aat   2544
Glu Arg Ser Gln Arg Leu Thr Glu Ser Val Asn Thr Ile Pro Asp Asn
        835                 840                 845

gcc acc gcc acc gcg gtg agc agc agc tca ctc acc aaa ttc aat ata   2592
Ala Thr Ala Thr Ala Val Ser Ser Ser Ser Leu Thr Lys Phe Asn Ile
    850                 855                 860

aat tca gca aag cca gcc gcc gcc gcc gat tcg cgt agc act ggc aca   2640
Asn Ser Ala Lys Pro Ala Ala Ala Ala Asp Ser Arg Ser Thr Gly Thr
865                 870                 875                 880

gat cca agt aca cca cag aac att cta cag att aaa gat ttg aat ttc   2688
Asp Pro Ser Thr Pro Gln Asn Ile Leu Gln Ile Lys Asp Leu Asn Phe
                885                 890                 895

ccc tca agg tcg tcg tct cgc ata tcc cag ccg gag ctg cac tac gcc   2736
Pro Ser Arg Ser Ser Ser Arg Ile Ser Gln Pro Glu Leu His Tyr Ala
            900                 905                 910

agc cta gat ctt ccc cat tgc agt ggc caa aat cca gct aaa tac ctg   2784
Ser Leu Asp Leu Pro His Cys Ser Gly Gln Asn Pro Ala Lys Tyr Leu
        915                 920                 925

aag aga gga tca cgc gaa tcg ccg ccg gtg tcc gca tgc ccg gag gat   2832
Lys Arg Gly Ser Arg Glu Ser Pro Pro Val Ser Ala Cys Pro Glu Asp
    930                 935                 940

ggg aat acc tat gcg aaa atc gac ttt gac caa tcc gac tcc tct tcc   2880
Gly Asn Thr Tyr Ala Lys Ile Asp Phe Asp Gln Ser Asp Ser Ser Ser
945                 950                 955                 960

tcc tca tcg aac ata ttt aat acg taa                              2907
Ser Ser Ser Asn Ile Phe Asn Thr
                965
```

<210> 3
<211> 969
<212> PRT
<213> Dosophila melanogaster

<400> 3

```
Met Ala Ser Ile Ser Asp Asp Gly Met Ala Leu Ser Gly Tyr Leu Lys
  1               5                  10                  15
```

```
Lys Leu Lys Thr Met Lys Lys Lys Phe Phe Val Leu Tyr Glu Glu Thr
            20                  25                  30

Ser Thr Ser Ala Ala Arg Leu Glu Tyr Tyr Asp Thr Glu Lys Lys Phe
        35                  40                  45

Leu Gln Arg Ala Glu Pro Lys Arg Val Ile Tyr Leu Lys Asn Cys Phe
    50                  55                  60

Asn Ile Asn Arg Arg Leu Asp Thr Lys His Arg Phe Val Ile Val Leu
65                  70                  75                  80

Ser Ser Arg Asp Gly Gly Phe Gly Ile Val Leu Glu Asn Glu Asn Asp
                85                  90                  95

Leu Arg Lys Trp Leu Asp Lys Leu Leu Val Leu Gln Arg Asn Ile Ala
            100                 105                 110

Asn Ser Asn Gly Thr Ala His Ser Pro Tyr Asp His Val Trp Gln Val
        115                 120                 125

Val Ile Gln Lys Lys Gly Ile Ser Glu Lys Val Gly Ile Thr Gly Thr
    130                 135                 140

Tyr His Cys Cys Leu Thr Ser Lys Ser Leu Thr Phe Val Cys Ile Gly
145                 150                 155                 160

Pro Glu Lys Thr Pro Asn Gly Glu Asp Arg Val Ala Ser Ile Glu Ile
                165                 170                 175

Leu Leu Thr Thr Ile Arg Arg Cys Gly His Ala Ser Pro Gln Cys Ile
            180                 185                 190

Phe Tyr Val Glu Leu Gly Arg Gln Ser Val Leu Gly Ser Gly Asp Leu
        195                 200                 205

Trp Met Glu Thr Asp Asn Ala Ala Ile Ala Thr Asn Met His Asn Thr
    210                 215                 220

Ile Leu Ser Ala Met Ser Ala Lys Thr Glu Ser Asn Thr Asn Leu Ile
225                 230                 235                 240

Asn Val Tyr Gln Asn Arg Pro Asp Leu Ser His Glu Pro Met Arg Lys
                245                 250                 255

Arg Ser Ser Ser Ala Asn Glu Ala Ser Lys Pro Ile Asn Val Asn Val
            260                 265                 270
```

Ile Gln Asn Ser Gln Asn Ser Leu Glu Leu Arg Ser Cys Ser Ser Pro
275 280 285

His Asn Tyr Gly Phe Gly Arg Glu Arg Cys Asp Ser Leu Pro Thr Arg
290 295 300

Asn Gly Thr Leu Ser Glu Ser Ser Asn Gln Thr Tyr Phe Gly Ser Asn
305 310 315 320

His Gly Leu Arg Ser Asn Thr Ile Ser Gly Ile Arg Pro His Ser Thr
325 330 335

Asn Lys His Ser Asn Ser Pro Thr Phe Thr Met Pro Leu Arg Cys Ser
340 345 350

Glu Ser Glu Glu Ser Ser Ile Ser Val Asp Glu Ser Asp Asp Asn Gly
355 360 365

Ser Phe Ser His Tyr Arg Leu Asn Thr Arg Ser Ser Glu Thr Ala Ile
370 375 380

Pro Glu Glu Asn Ile Asp Asp Phe Ala Ser Ala Glu Leu Phe Ser Lys
385 390 395 400

Val Thr Glu Gln Asn Val Ser Asp Glu Asn Tyr Ile Pro Met Asn Pro
405 410 415

Val Asn Pro Thr Asp Ala Ile His Glu Lys Glu Lys Ala Asp Met Gln
420 425 430

Arg Leu Glu Asp Ala Ser Leu His Phe Asn Phe Pro Glu His Ala Ser
435 440 445

Glu Lys Leu Ala Lys Asp Phe Asp Leu Asp Ser Asp Asn Gln Cys Cys
450 455 460

Arg Pro Ile Arg Ala Tyr Ser Ile Gly Asn Lys Val Glu His Leu Lys
465 470 475 480

Phe Asn Lys Arg Leu Gly His Leu Asn Asp Thr Gly Gln Asn Pro Asn
485 490 495

Arg Val Arg Ala Tyr Ser Val Gly Ser Lys Ser Lys Ile Pro Arg Cys
500 505 510

Asp Leu Gln Arg Val Val Leu Val Glu Asp Asn Lys His Glu Phe Thr
515 520 525

Ala Asn Arg Ser Gln Ser Ser Ile Thr Lys Glu Gly Thr Ser Tyr Gly
530 535 540

Ser Ser Ala Asn Arg Gln Lys Lys Ser Thr Ser Ala Pro Leu Leu Ser
545 550 555 560

Leu Lys Asn Gln Ile Asn Ser Asp Arg Met Ser Asp Leu Met Glu Ile
565 570 575

Asp Phe Ser Gln Ala Thr Asn Leu Glu Lys Gln Lys Phe Ile Lys Asn
580 585 590

Asn Glu Ile Pro Lys Tyr Ile Glu Asn Val Phe Pro Lys Ala Pro Arg
595 600 605

Thr Asp Ser Ser Ser Leu Thr Leu His Ala Thr Ser Gln Lys Asp Ile
610 615 620

Phe Asn Gly Thr Lys Leu Asn Asn Thr Ala Ile Thr Ser Glu Asp Gly
625 630 635 640

Tyr Leu Glu Met Lys Pro Val Gly Asn Gly Tyr Thr Pro Ser Ser Asn
645 650 655

Cys Leu Pro Met Lys Val Glu Lys Leu Lys Leu Ser Asp Tyr Gln Thr
660 665 670

Ala Pro Pro Leu Thr Ala Thr Ala Ala Pro Val His Asp Leu Asn Lys
675 680 685

Ile Ser Thr Tyr Asn Ile Ser Ala Glu Lys Trp Arg Glu Gln Pro Ser
690 695 700

Arg Ser Glu Glu Lys Lys Ser Asn Ser Pro Leu Asn Asp Asn Thr Phe
705 710 715 720

Ser Ser Lys Pro Thr Asn Val Glu Ser Thr Ser Lys Ser His Asp Val
725 730 735

His Ser Ala Asn Gln Ile Asp Cys Glu Lys Val Cys Ala Gln Ser Ser
740 745 750

Asp Lys Leu Asn Asn His Leu Ala Asp Lys Ile Val Glu Asn Asn Asn
755 760 765

Leu Asp Ile Gly Gly His Glu Glu Lys Lys Leu Val His Ser Ile Ser
770 775 780

Ser Glu Asp Tyr Thr Gln Ile Lys Asp Lys Ser Asn Asp Phe Thr Lys
785 790 795 800

Phe Asn Glu Ala Gly Tyr Lys Ile Leu Gln Ile Lys Ser Asp Ser Ser
805 810 815

Leu Ile Ser Ser Lys Leu Tyr Gln Lys Gly Ile His Lys Asp Asn Leu
820 825 830

Glu Arg Ser Gln Arg Leu Thr Glu Ser Val Asn Thr Ile Pro Asp Asn
835 840 845

Ala Thr Ala Thr Ala Val Ser Ser Ser Ser Leu Thr Lys Phe Asn Ile
850 855 860

Asn Ser Ala Lys Pro Ala Ala Ala Ala Asp Ser Arg Ser Thr Gly Thr
865 870 875 880

Asp Pro Ser Thr Pro Gln Asn Ile Leu Gln Ile Lys Asp Leu Asn Phe
885 890 895

Pro Ser Arg Ser Ser Ser Arg Ile Ser Gln Pro Glu Leu His Tyr Ala
900 905 910

Ser Leu Asp Leu Pro His Cys Ser Gly Gln Asn Pro Ala Lys Tyr Leu
915 920 925

Lys Arg Gly Ser Arg Glu Ser Pro Pro Val Ser Ala Cys Pro Glu Asp
930 935 940

Gly Asn Thr Tyr Ala Lys Ile Asp Phe Asp Gln Ser Asp Ser Ser Ser
945 950 955 960

Ser Ser Ser Asn Ile Phe Asn Thr
965

<210> 4
<211> 5210
<212> DNA
<213> Dosophila melanogaster

<400> 4
agaacgactt tttcctcctt agtcagtcac aagaaaacta aagcttacca acaatacggc 60

gtgtattgtt aaattattac aacaaataaa atattcaaat tgtatttaaa aatatagtaa 120

ccattaaaaa ataaaatcaa tatgcgaaac tttgtaattt cttactcatc cttgtttttt 180

gagcccgctt tcttaagtta aatcgttaaa ataccagttt aatcatttca ttgtcctgat 240

ttcaggagct aattacattt taatctttgt ataaattcat aaaattaaaa tggaaatgtt 300

taaccacata aaatatttgg gtatataaag tcgatacata cttttaaaat tttgtttcat 360

acaagaatat ggaaagtaga taatttagtt accgattaaa acatttctaa aatacaaaaa 420

atttaaaatg atgattaaat aaaaaactgt tatactaaat ttaaacgaaa caaacggtca 480

ttcgataact caattagtat cgaataagcc ggcgtgtaaa tcgggttggc aactctcacc 540

ggtgtagaga tcgggatggc aacttcgtat tgttattcct atgctgcgat aacgataaca 600

gcaaagtgtc atcgcgaata aatgtgggtt tgataataaa gaattgcgtt ggtgaacaat 660

aataatacaa atgctaaatg tatcgcgcgg ataactagta aacactgatt tcgcgcatat 720

cgggcatacg ggcagctaga cgtcttaggt aacacatttc ccagccacat tggcgttgag 780

gtattatttc ccatatccat gtgcgtttgt aaatgatacc accagagtgt gccatatgta 840

tcgttgtttg tacatacatg cctacgggga aaaataactc gcagatacat atgtatgtaa 900

gatgtattag aattccacag atatatgtac atataaatat atatatatat ttatgatgct 960

catctataaa acaaaatatg tacaaacata cgcgcgcacg tacttatgta tgtacatata 1020

catatataca tatatgtata ataaaatgag catctagctg cggttatctt aatgcaatgc 1080

gcagaaacct gaaaacgaaa taaacaatct ttacagcgcc agcacagtga gccaattatg 1140

aattcacaat tccacatcca attccgattc cgaattccat cgctttacat cctaattcga 1200

atacgtcgcg ccgcgtaagc tgcactcgaa tattgacata aacgacgtaa ttgcgtgttt 1260

tgattgcgat ttccgatgct cgatgttgac agacggcaag gatttttttt gccagccgac 1320

attgcgaatg cttttcgcgt gtttgcgttg tgaaaagcga tttgttgttc cggcagttgg 1380

aaatgttttg tgctgtttat gcttagaaaa gcaaatgtat tgcacaaaac tcgtgtttcc 1440

tacattagta aagcctataa cttaggtata tgtttctaaa ttacaatgca aaaaataaaa 1500

aacattatac atgtgttcgt tctttaattt gaaaacagaa aagtgaaagc cttgcaaatc 1560

aaatatgtgt ccatatcgcc tactaataat ataaacacgt cgccttccag gaactaagat 1620

tggaaatcat ggcatcaata tcggatgacg gcatggcgct gagtggctac ctcaagaagc 1680

tgaagaccat gaagaagaag ttctttgtgc tgtacgagga gacgagcact tcggcagccc 1740

ggctggagta ctacgatacc gaaaagaagt tcctgcaaag agccgagcca aaaagggtta 1800

tctatctgaa gaattgcttc aacatcaatc gccgtttgga caccaagcat agatttgtca 1860

ttgtgctctc ctccagagac ggtggattcg gcatcgttct cgagaacgaa aatgatttac 1920

gcaaatggtt ggacaaacta ctagttctac aaaggaacat agccaattcg aatggaacag 1980

cgcactcacc ttatggtatg ccaaataaac tataactacc agttagtatg aaacctaaac 2040

acttcatttc actttgcaga ccacgtttgg caagttgtca ttcaaaagaa gggtatttcg 2100

gagaaagttg gaatcaccgg aacctaccac tgttgcctta cttcaaaatc cctgacattc 2160

gtgtgcattg gaccggagaa gacgcccaat ggcgaggatc gcgttgcgag cattgaaata 2220

cttttgacca cgatcaggcg gttagttgtt gccagcaaaa ctgcaaggga ttgtaaaata 2280

attcggactt aatttcagat gcggtcatgc atccccacaa tgtatattct acgtggaact 2340

tggccgccaa agtgtcttgg gatctggtga tctgtggatg gagacggata acgcagctat 2400

tgctactaat atgcacaaca cgatactgag gtatttagct ctcattacaa ctaatccaag 2460

atttcatgat catcctacaa aacgacatag atagtttaag atatctccca gttaacttta 2520

ataattctgt gggtttttc tttcagcgct atgtcagcca aaacagagtc gaacacgaat 2580

ttaataaacg tttatcagaa cagacctgac ttaagtcacg agcccatgag aaagcgatcg 2640

tcgtctgcaa acgaagcatc gaagccgata aacgtaaatg tcatacaaaa tagtcaaaac 2700

tctctcgaat tgcgcagctg cagttcgccc cataactatg gtaaatactt caaatgtatg 2760

tttaaacgca aaattaatca aacgcaatcg tttcaggttt cggcagagag agatgcgata 2820

gcttaccaac cagaaatgga accctaagcg agtccagcaa tcaaacgtac tttggttcca 2880

accatggact gcgatccaat actatatctg gcatccgtcc gcactcaacc aacaagcata 2940

gtaatagtcc aacgttcacc atgccattaa gatgctcaga atccgaagag tcatcaatta 3000

gtgtcgatga atccgacgac aacggcagtt ttagccacta cagattaaag tgcgttgcta 3060

tcaaataata attatttaat aataatcacc atttcaattt ctagcacgcg gtcatctgag 3120

acggcaattc ctgaggaaaa cattgatgac tttgccagtg cggaattatt tagcaaagtc 3180

accgaacaaa atggtaagcc aaacacaaaa acaatttttt aacatgaaaa gtagctaatc 3240

aattggcttt gtttaactgc agtaagtgac gaaaactaca taccgatgaa tccagtcaat 3300

cctaccgatg ctatccatga aaaggagaag gctgatatgc agagattgga agatgcttcg 3360

ctgcatttca actttccgga gcacgcgtcg gaaaagcttg ctaaggattt tgatctggac 3420

tctgataacc agtgagtaca catttcgctt caactgtgcc acgtaatgca atcaatcaca 3480

tcttgttaca gatgctgtcg tcccattcgc gcctattcga taggcaacaa ggttgagcat 3540

ttaaagttta ataagcgcct gggacacttg aatgatacgg gacagaatcc gaatcgcgtg 3600

cgagcctact cggttggctc caaatcgaag ataccgcgct gcgacctgca gcgagtggtc 3660

ctcgtggagg acaataaaca tgagttcaca gcgaatagga gtcagagtag cattaccaag 3720

gaaggaacca gctatggcag cagtgccaat cgacaaaaga agtccacaag tgctccactc 3780

ctcagtctga agaaccagat aaactccgac cgaatgagtg acttaatgga aattgatttt 3840

tcacaagcaa ccaatttgga aaagcagaag ttcatcaaga ataatgaaat tccgaaatac 3900

attgaaaacg tgttcccaaa agccccgcga acggatagct ccagcctaac tctgcacgcc 3960

acaagtcaaa aggacatttt caatggcacc aaactaaata acactgcgat cacatccgag 4020

gatggttacc tcgagatgaa gccagtcggt aatggataca ctcccagttc gaattgcctg 4080

ccaatgaaag tggagaggct caagctatcc gactatcaga cagcaccgcc aatcaccgca 4140

acagccgcac cagtgcacga tttaaacaaa attagcacat acaatatatc cgctgagaaa 4200

tggagagaac agcccagcag aagcgaggaa aagaagtcga actcgccatt gaatgacaac 4260

acctttggct tgaaacccac aaatgtcgag agtacaagca aaagccatga tgttcattca 4320

gcaaatcaaa ttgattccga gaaagtgtgc gcgcagagca gcgataagct aaataatctg 4380

gccgacaaga ttgtcgagaa caacaatttg gatataggcg ggcatgagga aaagaagttg 4440

gttcattcga taagcagcga agactacaca caaatcaagg acaaatcgaa tgatttcaca 4500

aaatttaacg aagccggcta caaaattctg caaattaaaa gcgacagctc actcatctca 4560

tcgaagctat accaaaaggg tatacacaag gataacttgg agcgttcgca gagacttacg 4620

gagagtgtga atacgattcc cgataatgcc accgccaccg cggtgagcag cagctcactc 4680

accaaattca atataaattc agcaaagcca gccgccgccg ccgattcgcg tagcactggc 4740

acagatccaa gtacaccaca gaacattcta cagattaaag atttgaattt cccctcaagg 4800

tcgtcgtctc gcatatccca gccggagctg cactacgcca gcctagatct tccccattgc 4860

agtggccaaa atccagctaa atacctgaag agaggatcac gcgaatcgcc gccggtgtcc 4920

gcatgcccgg aggatgggaa tacctatgcg aaaatcgact ttgaccaatc cgactcctct 4980

tcctcctcat cgaacatatt taatacgtaa agttttgaaa tttatgaccc tatcctatat 5040

atatgatttg tttaatattg tacatttatt gtaaatattc tctgacaagc aaagcttaca 5100

attttggatg ctaataaata aattttattt aaattataat gatccctttg gacttttttt 5160

ttttttggac taagaaatca ctactaaaga agggctttc gagggttaaa 5210